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ABCA1, ATP-binding cassette transporters A1 
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ALOX3, epidermis-type LOX-3  
ALOX5, 5(S)-LOX 
ALOX8, 8(S)-lipoxygenase 
ALOX12, platelet-type 12(S)-LOX 
ALOX12B, epidermis-type 12(R)-LOX 
ALOX15, 15-lipoxygenase, reticulocyte-type 15(S)-LOX-1 
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CREB, cAMP-responsive element binding protein 
CTL, cytotoxic T cell 
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HNC, head an neck carcinoma 
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HPETE, hydroxyperoxyeicosatetraenoic acid  
HPODE, hydroperoxyoctadecadienic acid  
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ILDL, intermediate density lipoproteins 
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IL-1ra, interleukin-1 receptor antagonist  
IL-2, interleukin 2 
IL-4, interleukin 4 
IL-5, interleukin 5 
IL-6, interleukin 6 
IL-8, interleukin 8 
IL-10, interleukin 10 
IL-13, interleukin 13  
IL-18, interleukin 18 
iNOS, inducible nitric oxide synthase  
KHK, koronare Herzkrankheit 
LDL, low density lipoproteins 
LDLR-/-, low density lipoprotein receptor knock-out 
LOX, lipoxygenase 
LOX-1, lectin-like oxLDL receptor 
12/15-LOX, 12/15-lipoxygenases 
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LTB4, leukotrienes B4  
MC, mast cell 
MCP-1, monocyte chemoattractant protein 1  
M-CSF, macrophage colony stimulating factor 
MI, myocardial infarction 
miRNA, Micro RNA, micro ribonucleic acid 
MMP, matrix metalloproteinase 
MPO, myeloperoxidase 
NF-κB, nuclear factor kappa B 
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PASMC, pulmonary artery smooth muscle cells  
PMN, polymorphonuclear neutrophil  
PPAR-γ, peroxisome proliferator-activated receptor gamma 
ROS, reactive oxygen species 
SMC, smooth muscle cell 
SNP, single nucleotide polymorphism 
SR, scavenger receptor 
SR-A, scavenger receptor A 
TG, triglycerides 
TGF-β, transforming growth factor beta  
Th, T helper cell 
TLR, toll-like receptor 
TNF-α, tumour necrosis factor alpha  
TRL, triglyceride-rich lipoproteins 
TSS, transcription start site 
uORF, upstream open reading frame 
VCAM-1, vascular cell adhesion molecule 1 
VEGF, vascular endothelial growth factors  
VEGFR-3, vascular endothelial growth factor receptor-3 
VLDL, very low density lipoproteins 
VSMC, vascular smooth muscle cells  
WHO, World Health Organisation 
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SUMMARY 
 
 Atherosclerosis is a chronic disease characterized by two main features, lipid 
retention and inflammation in the arterial wall. There is evidence that 12/15-lipoxygenase 
plays a dual role in atherosclerosis with an anti-inflammatory effect through generation of 
lipid mediators and a pro-inflammatory and pro-atherogenic effect through lipid oxidation and 
contributing to signalling pathways. In human genetic case control studies, two 
polymorphisms in the 15-lipoxygenase, ALOX15, gene indicated a trend to be associated 
with coronary artery disease (CAD) suggesting a neutral to an atheroprotective role of this 
enzyme, but did not consistently show an association with all clinical end points of 
atherosclerosis. The second human 15-lipoxygenase, ALOX15B, discovered in 1997, has 
been shown recently to be expressed in human atherosclerotic plaques. For a better 
understanding of the role of ALOX15B in atherosclerosis, I investigated in this thesis the 
regulation of the expression of the different 12/15-lipoxygenases in human macrophages and 
investigated the association of polymorphisms in the ALOX15B gene with CAD. 
     I found that ALOX15B is the main expressed 12/15-lipoxygenase in human 
macrophages. Furthermore, stimulation of human macrophages with different cytokines and 
hypoxia revealed that interleukin-4 (IL-4), lipopolysaccharide (LPS) and hypoxia increased 
the expression of ALOX15B on mRNA and protein level. Interleukin-13 (IL-13) also enhanced 
ALOX15B mRNA but not protein expression. The expression of ALOX15 mRNA and protein 
was increased after IL-4 and IL-13 similar to the previously described increase in human 
monocytes.  In the second part of my project I found that the non-coding and synonymous 
polymorphisms at positions c.1458-38G>C, c.1579+71C>T and c.1656G>A which showed a 
perfect linkage disequilibrium are associated with CAD (OR: 0.51 (0.27-0.94), p-value: 0.03). 
Additionally, the synonymous mutation at position c.705C>T (OR: 0.80 (0.62-1.03) p-value: 
0.09) and the non-synonymous SNP at position c.1967A>G (p.Gln656Arg) (OR: 0.81 
(0.62-1.04), p-value: 0.10) showed a trend to be associated with CAD. However, functional 
enzyme assays revealed that the three non-synonymous SNP’s (p.Arg486His, p.Gln656Arg 
and p.Ile676Val) did not differ in their enzyme activities and kinetic behaviour compared to 
the wild-type form.  
In summary, I found in vitro that ALOX15B is the main 12/15-lipoxygenase expressed 
in human macrophages and is regulated by several cytokines and hypoxia, which have been 
suggested to play particularly a pro-atherosclerotic role. The association study of 
polymorphisms in the ALOX15B gene with CAD in our case control study revealed that three 
rare and completely linked variants are associated with CAD and that the non-synonymous 
but non-functional SNP c.1967A>G (p.Gln656Arg) showed a trend for an association with 
CAD. However, as our case control study is too small to exhibit the power for a clear answer, 
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these results are hypothesis generating and larger studies with the necessary power are 
required to specify the role of ALOX15B on atherosclerosis in humans based on my findings. 
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ZUSAMMENFASSUNG 
 
 Arteriosklerose ist eine chronische Erkrankung charakterisiert durch hauptsächlich 
zwei Merkmale, Ablagerung von Lipiden und Inflammation in der Arterienwand. Vieles deutet 
darauf hin, dass die 12/15-Lipoxygenasen eine zweifache Rolle in der Arteriosklerose 
spielen; einerseits haben sie einen anti-inflammatorischen Effekt durch die Bildung von Lipid 
Mediatoren, anderseits haben sie einen pro-inflammatorischen und pro-atherogenen Effekt 
durch die Oxidation von Lipiden und deren Einfluss auf Signalwege. In human genetischen 
Fall-Kontroll-Studien haben zwei Polymorphismen im Gen der 15-Lipoxygenase, ALOX15, 
einen Trend für eine Assoziation mit der koronaren Herzkrankheit (KHK) gezeigt, was eine 
neutrale oder sogar eine atheroprotektive Rolle dieses Enzyms vermuten lässt. Allerdings 
wurde diese Assoziation nicht mit allen klinischen Endpunkten der Arteriosklerose gefunden. 
Die zweite 15-Lipoxygenase, ALOX15B, entdeckt im Jahr 1997, wurde kürzlich ebenfalls in 
humanen atherosklerotischen Plaques identifiziert. Um die Rolle von ALOX15B in der 
Arteriosklerose besser zu verstehen, habe ich in dieser Doktorarbeit die Regulation der 
Expression von verschiedenen 12/15-Lipoxygenasen in humanen Makrophagen untersucht 
und die Assoziation von Polymorphismen im ALOX15B Gen mit der KHK ermittelt.  
 Ich habe herausgefunden, dass ALOX15B die am meisten exprimierte 
12/15-Lipoxygenase in humanen Makrophagen ist. Des Weiteren zeigte die Stimulation von 
humanen Makrophagen mit verschiedenen Zytokinen und mit Hypoxie, dass Interleukin 4 
(IL-4), Lipopolysaccaride (LPS) und Hypoxie die Expression von ALOX15B auf RNA und 
Protein Ebene erhöhen. Interleukin 13 (IL-13) steigert auch die Expression der ALOX15B 
RNA aber nicht die des ALOX15B Proteins. Die Expression von ALOX15 RNA und Protein 
war nach der Stimulation mit IL-4 und IL-13 erhöht, wie es schon in Monozyten beschrieben 
wurde. Im zweiten Teil meines Projektes haben meine Resultate ergeben, dass die 
nicht-kodierenden und synonymen Polymorphismen an den Positionen c.1458-38G>C, 
c.1579+71C>T und c.1656G>A (OR: 0.51 (0.27-0.94), p-value: 0.03) ein perfektes Linkage 
Disequilibrium aufweisen und mit der KHK assoziiert sind. Zusätzlich haben der synonyme 
Polymorphismus an der Stelle c.705C>T (OR: 0.80 (0.62-1.03) p-value: 0.09) und der 
nicht-synonyme Polymorphismus an der Stelle c.1967A>G (p.Gln656Arg) (OR: 0.81 
(0.62-1.04), p-value: 0.10) einen Trend für eine Assoziation mit der KHK gezeigt. Allerdings 
führte keine der drei synonymen Polymorphismen (p.Arg486His, p.Gln656Arg und 
p.Ile676Val), die ich in der Fall-Kontroll-Studie identifiziert habe, zu einer veränderten Enzym 
Aktivität oder zu einem veränderten kinetischen Verhalten verglichen zum Wildtyp. 
 Zusammenfassend konnte ich zeigen, dass in vitro in humanen Makrophagen 
ALOX15B die hauptsächlich exprimierte 12/15-Lipoxygenase ist, die von verschiedenen 
Zytokinen und der Hypoxie reguliert wird, welche eine eher pro-atherosklerotische Rolle 
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spielen. In der Assoziationsstudie mit unserer Fall-Kontroll-Studie sind drei seltene und 
vollständig gelinkten Varianten im ALOX15B Gen mit der KHK assoziiert und der 
nicht-synonyme aber nicht-funktionelle SNP c.1967A>G (p.Gln656Arg) zeigt einen Trend für 
eine Assoziation mit KHK. Da unsere Fall-Kontroll-Studie zu klein ist um eine abschliessende 
Aussage über die Assoziation der ALOX15B mit der KHK zu machen, generieren meine 
Resultate eine Hypothese, die in Studien mit einer grösseren Anzahl Teilnehmer und somit 
grösser Aussagekraft beantwortet werden sollte, um die exakte Rolle von ALOX15B in 
humanen Arteriosklerose zu bestimmen. 
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1. INTRODUCTION 
 
1.1 Atherosclerosis 
 
1.1.1 Risk factors and treatment strategies  
 
Atherosclerosis is a multifactorial disease and is the primary cause of coronary artery 
disease (CAD), myocardial infarction (MI) and stroke. According to the World Health 
Organization (WHO, 2008) ischaemic heart disease, stroke and other cardiovascular 
diseases are the major causes of death in developed countries. Many hereditary diseases 
such as familial hypercholesterolemia have been associated with atherosclerosis, however in 
most of these cases the progression and sequelae of atherosclerosis result from the 
interaction of both multiple genetic and environmental factors. In the pathogenesis of 
atherosclerosis, an imbalance in lipid metabolism and  a maladaptive immune response 
cause a chronic inflammation in the arterial wall that occurs at predilection sites with 
disturbed laminar flow [1]. Besides the well-known cardiovascular risk factors such as 
hypertension, smoking, overweight and dyslipidemia, a number of recently identified and less 
well-known factors have emerged and received much interest over the past few years. 
Knowledge regarding these newer risk factors, including impaired fasting glucose, 
triglycerides, lipoprotein (a), homocysteine and high-sensitivity C-reactive protein, may 
further improve the ability to predict future risk of cardiovascular disease when added to the 
classical risk factors. Fruchart et al. proposed to classify the risk factors into three groups 
including old, old/new and new as outlined in table 1 [2]. 
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Old Old/New New 
Sex (men>women) High-normal blood pressure Apolipoprotein B, 
apolipoprotein A-I 
Age Metabolic syndrome Triglycerides; triglyceride-rich 
lipoprotein remnants 
Family history of premature 
cardiovascular disease 
Diabetes mellitus; impaired 
glucose tolerance; impaired 
fasting glucose 
Small dense LDL; oxidized 
LDL; antibody against oxidized 
LDL 
Total cholesterol; LDL 
cholesterol; HDL cholesterol 
(neg.factor) 
 Lipoprotein (a) 
Hypertension  Homocysteine 
Smoking  High-sensitivity C-reactive 
protein 
Overweight/obesity   
Table 1: Old, old/new and new risk factors for atherosclerosis [2] 
 
AGLA, the Swiss society of atherosclerosis, provides a tool for the identification and 
treatment of the risk factors of atherosclerosis and gives recommendations to physicians. On 
their webpage they give recommendations for treatment strategies of patients with a 
beforehand evaluated risk category. The risk category is classified into four groups: Very 
high risk, high risk, intermediate risk and low risk as outlined below. The 10-year risk can be 
calculated on their webpage by supplying information about age, sex, blood pressure, lipid 
status and family history. 
 
Very high risk - Known coronary heart disease/atherosclerosis 
- Diabetes Typ2 or Typ1 with organ damage 
- GFR < 60 ml/min/1.73m2 
High risk - 10-year risk > 20% 
- Very high single risk factors like LDL > 4.9 mmol/l or  BP > 160/100      
   mmHg 
Intermediate risk 10-year risk 10 – 20% 
Low risk 10-year risk < 10% 
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On the one hand it is beneficial for a patient to know their own risk category and on 
the other hand it is of interest to identify the treatment strategies for patients with an 
increased risk. The current treatment strategies include, besides the primary intervention 
goal of changing the lifestyle with a healthier diet, the reduction of obesity, the increase in 
exercising and stopping of smoking, the pharmacological treatment of dyslipidemia and other 
risk factors including diabetes mellitus, hypertension and disturbed haemostasis 
(www.agla.ch). 
However, these current strategies do not consider the inflammatory aspect of 
atherosclerosis which drives the progression. Further, in some patient even when treated 
with lipid-lowering drugs like statins, a large residual risk of cardiovascular events remains 
[3]. Therefore, new targets for an improved therapy are warranted. In a recent publication, 
Weber et al. summarized the established, emerging and future concepts in the therapy of 
atherosclerosis (table 2). There are several promising therapeutic approaches in clinical 
phase 1 - 3 including the HDL mimetics apoa1-Milano, Darapladib, an inhibitor of 
lipoprotein-associated phospholipase A2 which is expressed abundantly in the necrotic core 
of coronary lesions [4], anti-inflammatory approaches such as the IL-1 receptor antagonist 
(IL-1ra) and the immunosuppressant Methotrexate. The emerging knowledge of the 
pathogenesis of atherosclerosis leads to novel experimental strategies which focus on the 
intervention of inflammatory and immune reactions, for example immunization with protective 
antibodies or blocking of pro-atherogenic chemokine receptors [1]. Although these new 
strategies show promise, they have to overcome many challenges until their approval and 
establishment as therapeutics.  
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Table 2: Established, emerging and new experimental concepts in the treatment of cardiovascular 
disease [1] 
 
1.1.2 General mechanism of atherosclerosis 
 
The events in the development of atherosclerosis have been explained by human 
pathological studies and experimental studies in mice. The normal coronary artery consists 
of 3 layers, the endothelial cells which are in contact with the blood, the intima which 
contains of a few smooth muscle cells (SMCs) widespread in the intimal extracellular matrix, 
and the media which has multiple layers of SMCs tightly packed and embedded in a matrix 
rich in elastin and collagen [5]. The earliest lesions are characterized by subendothelial 
accumulation of lipid-loaded macrophages called foam cells [6]. These foam cells can form 
fatty streaks, which can be the precursors of more advanced lesions or eventually disappear, 
are prevalent already in young people and are not clinical significant [7, 8]. Further, 
accumulation of lipid-rich necrotic debris, inflammatory cells and SMCs in the intima leads to 
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the formation of early atheroma or atheromatous plaque which typically has a fibrous cap 
composed of SMCs and extracellular matrix [6]. The ongoing progression of this plaque 
includes more complex processes such as calcification, ulceration at the luminal surface and 
haemorrhages from small vessels which originate from the blood vessel wall [9-11]. The 
development of the plaque can go in two directions, to become either a stabilized plaque with 
a thick fibrous cap or an unstable vulnerable plaque. These advanced lesions can grow into 
the lumen disturbing the blood flow, but the rupture of a vulnerable plaque - which is 
characterized by thin fibrous cap and increased number of inflammatory cells - leading to a 
thrombus and eventually a MI or stroke is the most important clinical complication (Fig.1) [12, 
13]. 
 
 
 
Figure 1: Stages of atherosclerosis. The normal coronary artery consists of 3 layers, the endothelial 
cells, the intima and the media. In the first stages of atherosclerosis, the accumulation of lipoproteins 
in the intimal region leads to an infiltration of monocytes into the vessel walls where they differentiate 
into macrophages. The uptake of lipoproteins by the macrophages leads to the formation of lipid-
loaded foam cells which can die, resulting in a necrotic core of lipid and cellular debris. The migration 
and proliferation of SMCs forms a fibrous cap overlying the necrotic core. The rupture of a vulnerable 
plaque leading to the formation of a thrombus is the most common cause of a myocardial infarction 
[12]. 
It has been described that as a first step in the development of an atherosclerotic 
plaque, the monolayer of endothelial cells which line the inner arterial surface (fig.1a) 
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undergoes a change when exposed to stimuli such as dyslipidemia, hypertension or 
pro-inflammatory mediators [14]. The increased plasma level of cholesterol-rich very low 
density lipoprotein (VLDL) and low density lipoprotein (LDL) leads to an infiltration and 
retention of lipids in the arterial intima [15], where they can be oxidized releasing bioactive 
phospholipids which in turn can activate endothelial cells [16]. The activated endothelial cells 
express several types of leukocyte adhesion molecules; these cause in a first step rolling of 
the blood cells on the vascular surface and in a second step adherence at the susceptible 
site [17, 18]. Consequently the leukocytes migrate through the endothelial layer into the 
intima guided by chemoattractant stimuli [19]. The most abundant white blood cells in the 
plaque, the monocytes, differentiate into macrophages which can uptake oxidized low 
density lipoprotein (oxLDL) by different receptors leading to the formation of foam cells [20] 
(Fig.1b). With time, the foam cells die and release their lipid contents into the extracellular 
space, contributing to the growth of the lipid-rich necrotic core [21]. In the further formation of 
the atheroma, the recruitment and proliferation of SMCs from the media into the intima 
occurs, and the production of extracellular matrix molecules lead to the formation of a fibrous 
cap which covers the plaques [22]. Besides the characteristics of the advance plaques 
(including fibrous cap, foam cells, the large necrotic core and cholesterol crystals), the 
calcification process, in which periocyte-like cells secrete a matrix scaffold that becomes 
calcified, neovascularisation and haemorrhaging contribute to the formation of the advancing 
plaques and might have an influence on their stability (Fig.1c) [23]. Although the plaques can 
cause clinical complications by flow-limiting stenoses or luminal narrowing, the most critical 
clinical manifestations are plaque rupture and thrombosis leading to MI or stroke [24]. 
Rupture occurs preferentially in vulnerable plaques with a thin fibrous cap, a relatively high 
concentration of lipid-filled macrophages within the shoulder region, an increased number of 
inflammatory cells and a large necrotic core [18, 25] (Fig.1d). Activated macrophages, T cells 
and mast cells produce several types of molecules such as inflammatory cytokines including 
interferon gamma (IFN-γ); this limits the synthesis of collagen, releases and activates 
proteases like matrix metalloproteinases (MMP) that degrade the extracellular matrix 
proteins, and stimulates coagulations factors, radicals and vasoactive molecules [21, 26, 27]. 
All of these events can cause the formation of a thinner cap and therefore lead to a 
destabilisation of the plaque and to the subsequent plaque rupture resulting in the exposure 
of lipids and tissue factors, starting the coagulation cascade, platelet adherence and 
thrombosis [1, 14, 18, 23, 28]. 
 
16 
 
 
Figure 2: Progress of the development of atherosclerotic lesions. a: The normal artery consists of 
three layers, the endothelial cells which are in contact with the blood, the intima which contains some 
SMCs and the media which has multiple layers of SMCs embedded in a complex extracellular matrix. 
b: In the first steps of atherosclerosis, the endothelial layer becomes activated and enables the 
migration of the leucocytes into the intima. Within the vessel wall, the monocytes differentiate into 
macrophages which can take up lipids and become lipid-loaded foam cells. c: Lesion progression 
involves proliferation and migration of SMCs, increased production of extracellular matrix molecules 
and accumulation of lipid and cellular debris from dying cells. Advanced plaques also contain 
microvessels. d: Plaque rupture occurs preferentially from vulnerable plaques with a thin fibrous cap, 
increased number of inflammatory cells and a large necrotic core, and can trigger thrombosis [23]. 
 
1.1.3 Lipids in atherosclerosis 
 
Atherosclerosis is a progressive disease and is characterized by lipid retention, 
oxidation and modification which cause chronic inflammation in the susceptible site of the 
arterial wall [29]. The oxidation theory of atherogenesis reveals that the oxidation of LDL is a 
key and early event and responsible for the lipid loading of macrophages leading to the 
formation of foam cells and possibly for other characteristics of atherogenesis [30, 31]. The 
two main lipids in plasma, cholesterol, either free or esterified, and triglycerides (TG), are 
transported in lipoproteins; these are pseudomicellar lipid-protein complexes with the main 
apolipoproteins, apo B-100/48, apo A-I, apo A-II, apo E and the apo Cs as the integral 
components [32]. The lipoproteins are commonly divided in the following major classes, the 
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chylomicrons (CM), VLDL, intermediate density lipoproteins (ILDL), LDL and high density 
lipoproteins (HDL) [33].  
LDL particles are the major carrier of cholesterol to peripheral tissues in the fasting 
state and elevated LDL level in plasma has been shown to be closely associated with a high 
risk of cardiovascular disease [23].  
A primary event in the initiation of atherosclerosis is the accumulation of plasma 
lipoproteins in the subendothelial matrix [15, 34]. These diffuse passively through endothelial 
junctions and are retained through a combination of interaction between apoB100 and the 
negatively charged extracellular matrix proteoglycans, as well as lipoprotein aggregation [35, 
36]. The retained lipoproteins, like LDL, undergo several modifications, for example oxidation 
through reactive oxygen species (ROS) or enzymes such as the myeloperoxidases (MPOs) 
or lipoxygenases (LOXs) released by inflammatory cells [12, 32]. This is one of the most 
significant modifications in the early event of atherogenesis, and leads to the release of 
bioactive lipids which can initiate inflammatory responses [16] and to the formation of 
macrophages-derived foam cells [37].  
OxLDL has many pro-atherogenic effects such as the stimulation of the production of 
inflammatory cytokines, chemokines and adhesion molecules by endothelial cells and 
monocytes, stimulation of the release of tissue factors, MMP as well as scavenger receptor 
(SR) expression by monocytes/macrophages, and stimulation of collagen synthesis in SMCs. 
Furthermore it can inhibit the production of nitric oxide (NO) which has anti-atherogenic 
properties such as vasorelaxation, and initiate immunogenic activity by increasing the level of 
antibody against oxidation specific epitopes [13, 32, 38]. OxLDL and oxLDL-derived 
molecules have been found in atherosclerotic plaques [39] as well as in plasma. The level of 
oxLDL in circulation has been shown to correlate with the severity of cardiovascular diseases 
providing a potential role as a predicting marker [40]. 
The three best studied receptors which recognize oxLDL are scavenger receptor A 
(SR-A), scavenger receptor B (CD36) and lectin-like oxLDL receptor (LOX-1). Endothelial 
cells primarily express LOX-1, a type II membrane protein; activation of LOX-1 might be 
responsible for the oxLDL and angiotensin II mediated biological effects such as blood 
pressure regulation. Angiotensin II, a blood pressure regulator and pro-inflammatory agent, 
conducts the vasoconstriction via the angiotensin II receptor 1 (AT1R). Angiotensin II and 
oxLDL influence each other as hypercholesterolemia increases the expression of the AT1R 
and the activation of AT1R in turn up-regulates LOX-1 expression [41, 42]. SR-A and CD36 
together are thought to be responsible for almost 90% of the oxLDL uptake by macrophages 
[38]. It has been shown that mice lacking either SR-A [43] or CD36 [44] have a modest 
reduction in atherosclerotic lesions, however this finding has been questioned recently by 
another mouse study in which the loss of SR-A or CD36 did not ameliorate atherosclerosis in 
hyperlipidemic mice, suggesting that an alternative lipid uptake mechanisms may contribute 
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to the macrophages cholesterol ester accumulation [45]. Additionally, in mice lacking both 
receptors, SR-A and CD36, the deletion of these two receptors did not abrogate macrophage 
foam cell formation or reduce atherosclerotic lesion but led to a reduced progression to more 
advanced necrotic lesions, suggesting that the inhibition of these pathways in vivo may 
promote less lesion inflammation and plaque stability [46]. Though the scavenger receptors 
seem to be involved in atherogenesis their exact function in its progression remains unclear 
[47]. 
Although an elevated LDL level is well establish as a major predictor of coronary 
heart disease risk, there is evidence that an elevated TG level is also an independent risk 
factor [48]. The fact that significant lowering of plasma LDL only results in a small reduction 
in total mortality supports the concept that additional atherogenic lipid factors such as 
triglyceride-rich lipoproteins (TRL), remnant lipoproteins and HDL, are involved in the 
pathogenesis of atherosclerosis [49].  
Triglycerides are mainly carried in form of TRL, i.e chylomicrons, and VLDL, and have 
been associated with coronary atherosclerosis [50]. Remnant lipoproteins, which are 
produced when TG in large TLR are hydrolyzed by lipases and are subsequently enriched in 
cholesterol, are internalized by cultured macrophages and are potent inducers of foam cell 
formation. Moreover they are abundant in the intima of atherosclerotic lesions and their 
increased plasma level has been associated with CAD [49].  
In several epidemiological studies it has been shown that the level of HDL correlates 
inversely with cardiovascular risk [51] and the current guidelines from the American Heart 
Association propose that HDL cholesterol levels higher than 1.0 mmol/l in men and 1.3 
mmol/l in women are atheroprotective [52]. Multiple mechanisms participating in this 
protection against atherosclerosis have been described, for example the removal of 
cholesterol from lipid-laden macrophages by reverse cholesterol transport, and the inhibition 
of LDL oxidation. Additionally, HDL has been shown to exhibit other anti-inflammatory 
properties, such as the inhibition of adhesion molecules expression as well as cytokine 
production in endothelial cells, the blocking of platelet activation and coagulation and 
stimulation of cell proliferation [51, 53, 54]. Hence, modification of HDL metabolism is thought 
to be beneficial for patients with CAD and is used as a secondary prevention treatment [1].  
The importance of the lipid metabolism in the onset of atherosclerosis has been used 
to generate different mouse models to study the progression of this disease. For example, 
the deletion of the apolipoprotein E gene in mice (ApoE-/-) leads to severe 
hypercholesterolemia and to spontaneous atherosclerosis. Mice lacking the LDL receptor 
(LDLR-/-) also develop atherosclerosis when fed a high fat diet. Such animal models are 
useful to study the mechanisms of the disease initiation and early growth. However, they are 
less suitable for the investigation of advanced stages in atherosclerosis involving plaque 
rupture or thrombosis because mice do not develop these stages. To investigate the late 
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stages of atherosclerosis, researchers still depend on histopathological and clinical studies 
[1, 55].    
 
1.1.4 Inflammation and immunity in atherosclerosis 
 
A prominent role of inflammation and immunity, including both the innate and 
adaptive immune responses, in the progression of atherosclerosis and its complications has 
become recognised over the past decade, resulting from the improvement in our knowledge 
of vascular biology [5]. A key observation which supports the concept of the implication of a 
chronic inflammation at every stage of atherosclerosis is the accumulation of leukocyte 
subsets in lesions at various stages, as well as the mediation of a wide range of cellular 
effectors in the inflammatory cascades [56]. Underlining this, several case control studies 
showed that in patients with chronic inflammatory diseases, the risk of CAD is significantly 
higher. For example, patients with rheumatoid arthritis have a 2-fold higher incidence of CAD 
[57], the presence of severe psoriasis has been shown to be a statistically significant risk 
factor for major adverse cardiac events [58], and in patients with systemic lupus 
erythematosus, a chronic autoimmune disorder, the risk of cardiovascular disease is more 
than 2-fold higher [59].  
The key early inflammatory event in atherosclerosis is the activation of endothelial 
cells by several irritating stimuli including phospholipid species generated during lipoprotein 
modification (e.g oxLDL) and turbulent blood flow leading to the expression of several 
leukocyte adhesion molecules on the endothelial surface layer [55]. Haemodynamic flow 
pattern and shear stress are important physical forces acting on the endothelial cells which 
can lead to an increased expression of adhesion molecules such as vascular cell adhesion 
molecule 1 (VCAM-1), and inflammatory genes such as nuclear factor kappa B (NF-κB) [60]. 
VCAM-1 expression can also be induced by pro-inflammatory cytokines such like interleukin 
1 beta (IL-1β) or tumour necrosis factor alpha (TNF-α) which in turn is also mediated in part 
by the NF-κB [61-63]. The selectins (P and E) expressed on the activated endothelial cells 
and their corresponding ligands expressed on leukocytes are mainly responsible for the first 
rolling and tethering of the circulating blood cells onto the vascular layer. In contrast, the 
VCAM-1 and intracellular adhesion molecules (ICAM-1) on the endothelial layer, as well as 
the corresponding integrins expressed on the blood cells conduct the leukocyte arrest and 
firm adhesion [64]. Once attached firmly, the leukocytes, i.e monocytes and lymphocytes, 
migrate through the inter-endothelial junctions into the subendothelial space in response to 
chemoattractant stimuli, including chemokines and lipid mediators which are produced in the 
intima [14]. Several chemokines and receptors seem to be involved in the recruitment of the 
leukocytes. These include monocyte chemoattractant protein 1 (MCP-1) and its 
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corresponding receptor CCR2 expressed on monocytes, T and B cells, RANTES or CCL5 
which binds to CCR1 receptor on T cells, T cell activating chemokines (e.g CXCL10) and 
their receptor (e.g CXCR3), eotaxin which is involved in the recruitment of eosinophils, and 
the transmembrane chemokine fractalkine (CX3CL1) which has chemoattractant function for 
CX3CR1+ mononuclear cells [65]. The importance of chemokines has been revealed in 
several animal studies, for example ApoE-/- mice lacking the MCP-1 receptor, CCR2, 
developed markedly fewer atherosclerotic lesions but had no difference in plasma lipid or 
lipoprotein concentrations [66]. Administration of a RANTES receptor antagonist reduced the 
progression of atherosclerosis in mice [67] and deletion of the CX3CL1 receptor in mice led 
to reduction of macrophage recruitment and decreased lesion formation [68]. Additionally, 
lipid mediators, a class of bioactive lipids formed by several specific biosynthetic pathways, 
have been shown to play a role in atherosclerosis, for example the leukotrienes and the 
enzymes necessary for their generation. The expression of these enzymes such as 
5-lipoxygenase and the leukotriene A4 hydrolase was increased in human atherosclerotic 
plaques and correlated with plaque instability [69]. There is evidence that the leukotrienes B4 
(LTB4) have pro-inflammatory properties by induction of adhesion, chemotaxis and 
transmigration of leukocytes, generation of superoxide and release of lysosomal enzymes 
from leukocytes [70, 71]. On the other hand, lipid mediators can also act in an 
anti-inflammatory way, for example the lipoxins which reduce chemotaxis, block the 
transmigration of neutrophils across epithelial cells and exhibit anti-inflammatory effects in 
animal models. Their role in human atherosclerosis however remains to be clarified [71].  
In the intima, the monocytes differentiate into macrophages stimulated by various 
factors such as the macrophage colony stimulating factor (M-CSF). In ApoE-/- mice with 
M-CSF deficiency, the decreased development of atherosclerosis revealed that this process 
is necessary for atherogenesis [72]. The differentiation is accompanied by the up-regulation 
of pattern-recognition receptors such as scavenger receptors and toll-like receptors (TLRs) 
which have impacts on foam cell formation and other macrophage-mediated processes. The 
detailed role of macrophages in the pathogenesis of atherosclerosis will be discussed in the 
next chapter.  
Beside the leukocytes, the platelets are one of the first cells appearing at the 
susceptible sites in the arterial wall and may contribute to the activation of endothelial cells. It 
has been demonstrated that activated platelets interact with endothelial cells in vivo and that 
blocking of platelet adhesion in ApoE-/- mice led to a reduced leukocyte accumulation in the 
arterial intima and to an attenuation of atherosclerotic lesion formation [73]. The interaction of 
activated platelets with endothelial cells leads to the release of chemokines and the 
expression of adhesion molecules contributing to the recruitment of leukocytes [74]. 
Furthermore, the activated platelets themselves release inflammatory mediators, form 
platelet-leukocyte aggregates, which promote the inflammatory reaction of the vessel walls, 
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[75] as well as platelet-monocyte complexes, which have been associated with ischaemic 
events [76]. In addition to the capability of cellular interactions, platelets are able to bind, take 
up and transport lipoproteins and thus might be involved in foam cell formation via 
phagocytosis by circulating monocytes and their subsequent migration into the vessel walls 
[77]. Hence, platelets play an important role in thrombus formation but are also involved in 
the initiation of atherogenesis as an inflammatory mediator and therefore participate in both 
early and late atherosclerosis. [74].  
In addition to the monocytes/macrophages, several more immune cells have been 
detected in the atherosclerotic plaques including T cells, B cells, dendritic cells (DCs), mast 
cells (MCs) and recently published neutrophils [78]. Immunodeficient mice lacking mature T 
and B cells (ApoE-/- scid/scid) developed much smaller lesions [79]; transfer of CD4+ T cells to 
these mice re-established the size of the lesion suggesting that CD4+ T cells are 
pro-atherogenic in mice [80]. T cells are recruited to the lesion site in parallel with 
macrophages in a similar way that involves adhesion molecules and chemokines [65], 
though they are less abundant [55]. The recruitment happens in an antigen-independent way 
but the activation of proliferation and expansion of the cells occurs after induction by antigens 
[65, 81-83]. T cells are divided into two major groups according to the co-receptor they 
express, the CD4+ (T helper cells, Th) and CD8+ (cytotoxic or cytolytic T cells, CTLs) 
groups. Analysis of atherosclerotic lesions in mice revealed that CD4+ cells were the 
dominating type in all phases of lesion progression. In fatty streaks, CD4+ cells were 
frequently found in form of clusters suggesting clonal proliferation, and in the atherosclerotic 
plaques, CD4+ were mainly located in the fibrous cap and subendothelial space. CD8+ cells 
are less prevalent than CD4+ cells but present in all stages of lesion progression and 
widespread in the tissue without cluster formation [84].  
CD4+ helper T cells can differentiate into two main subtypes, the type 1 helper cells 
(Th1) and the type 2 helper cells (Th2). The Th1 cells, which secrete IFN-γ, interleukin 2 
(IL-2) and TNF-α, give rise to a pro-inflammatory response by activating macrophages and 
reacting in a delayed-type hypersensitivity thereby functioning in the defence against 
intracellular pathogens. The Th2 cells produce the cytokines IL-4, interleukin 5 (IL-5) and 
IL-13 which are involved in the allergic reaction, as well as interleukin 10 (IL-10) which elicits 
an anti-inflammatory response [14, 85, 86]. In atherosclerotic plaques, the pro-inflammatory 
Th1 cytokines IL-2 and IFN-γ have been prevalently found in a large proportion of plaques, 
whereas the Th2 cytokines IL-4 and IL-5 were observed only rarely, demonstrating the 
presence of a predominately pro-inflammatory Th1 response in atherosclerosis [87]. Several 
mouse models provide evidence that Th1 cells play a major role in the pathogenesis of 
atherosclerosis. Examples include the deletion of IFN-γ receptor in ApoE-/- mice which leads 
to smaller lesion formation with a lower lipid content [88], and mice lacking interleukin 18 
(IL-18), a Th1 promoting cytokine, which developed smaller lesions [89], suggesting a 
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pro-atherosclerotic effect of Th1 cells. Although Th2 cells have been detected rarely in 
atherosclerotic plaques, they might play a role in atherogenesis; BALB/c mice that elicited a 
CD4+ Th2 (IL-4+) cell response were protected from early fatty streak development [90]. On 
the other hand, IL-4 deficient ApoE-/- mice developed fewer atherosclerotic plaques indicating 
a pro-atherogenic role of endogenous IL-4 [91]. However, another report did not find an 
effect of IL-4 administration to ApoE-/- mice on the development of atherosclerotic plaques 
[92]. Therefore, these contradictory results did not indicate a clear atheroprotective role for 
the Th2 question, and the switching of the immune answer from a Th1 to a Th2 answer may 
not be beneficial in halting the development of atherosclerosis. 
CD8+ T cells are less abundant than CD4+ T cells in atherosclerotic lesions [22] and 
it has been shown that CD8+ deficiency in mice did not influence atherosclerosis [93]. 
However, there is evidence that they may yet contribute to atherosclerosis; activation of 
CD8+ T cells with an antigen of artificial smooth muscle markedly exacerbated 
atherosclerosis in ApoE-/-  mice [94], and CD8+ T cells are implicated in the accelerated 
atherosclerosis in patients with systemic lupus erythematosus [95].  
Although only a few B cells are detected in atherosclerotic lesions [22], they are 
thought to have anti-atherosclerotic activity, as underlined by several studies [55]. For 
example, transfer of splenic B cells from aged atherosclerotic ApoE-/- mice has a protective 
effect on splenectomised recipients [96]. In this process, though bacterial and viral 
pathogens have been detected in atherosclerotic plaques, it is thought that the auto-antigens 
LDL and the heat shock protein 60 (Hsp 60), which are up-regulated in response to several 
forms of stress, are potentially important for the triggering of the adaptive immune response 
[55]. Antibodies against oxidized LDL have been found in atherosclerotic plaques [97], as 
well as in blood circulation of patients [98]. Additionally, immunization of 
hypercholesterolemic rabbits with oxLDL reduced the occurrence of atherosclerotic lesions 
[99]. Antibodies of members of the Hsp 60 family are associated with atherosclerosis and are 
thought to be involved in the immune reactions in the earliest stages of atherosclerosis as 
the main antigen [100].   
Dendritic cells are specialized for capturing, processing and presenting antigens to T 
cells, and consist of several subtypes each with specific functions and particular location in 
the immune system [101]. DCs are present in an increased number in atherosclerotic 
arteries. They become activated and differentiated at earlier stages; in advanced lesions they 
are found mainly in the exposed plaque shoulder, suggesting that DCs might contribute to 
the plaque destabilization through the activation of T cells [102, 103].   
Mast cells have also been found in atherosclerotic plaques mainly in the shoulder 
region of atheromas [104] as well as around the intraplaque microvessels, suggesting that 
they might contribute to haemorrhaging and thereby leading to unstable plaques formation 
[105]. They are involved in allergic reactions and can release proteases such as tryptase, 
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chymase and cathepsin G, histamine, heparin proteoglycans, lipid mediators such as 
platelet-activating factors and prostaglandin D2, growth factors such as vascular endothelial 
growth factors (VEGFs), and cytokines namely interleukin 6 (IL-6) and IFN-γ. MC might have 
many functions in atherogenesis, for example, they have been shown to increase the oxLDL 
uptake by macrophages [106]. Furthermore, MCs are thought to contribute to the weakening 
of the fibrous cap by activation of MMPs or by inhibition of collagen synthesis in SMCs [107, 
108].  
There is emerging evidence that neutrophils might also play a role in atherogenesis. 
Neutrophils are phagocytes and the prominent leukocytes in an acute inflammatory response 
to invading pathogens or tissue injury in which they eliminate microbial pathogens by 
endocytosis or by release of various molecules such as ROS, MPO and proteolytic enzymes. 
Beside their eliminating function, the neutrophils also produce leukotriene B4 (LTB4), a lipid 
mediator, which can recruit the leukocytes to the site of infection or secrete cytokines which 
can promote pro-inflammatory effects [109]. In LDLR-/- mice it has been shown that 
neutrophils are present in different intermediate and advanced stages of atherosclerosis but 
not in the early lesions [110]. In humans, several studies indicate a direct or indirect 
involvement of neutrophils in atherosclerosis; an association between the presence and 
severity of CAD and the localisation of neutrophils in human lesions has been found [78, 
109].   
The implication of infectious agents to the development of atherosclerosis has been 
established for a while, with the main research being focussed on Cytomegalovirus (CMV) 
and Chlamydia pneumoniae. However, this association has been questioned by several 
recently published studies and remains to be elucidated [111].   
Serological studies of an association between C. pneumoniae antibodies [111] and 
atherosclerosis, as well as the detection of C. pneumoniae in macrophages, SMCs, and early 
(fatty streak) and late (fibrous plaque) atherosclerotic lesions [112] suggest that C. 
pneumoniae might play a pathogenic role in atherosclerosis. Several mechanisms have been 
described regarding how this bacterium could affect atherogenesis [113]. For example, the 
infection of endothelial cells led to stimulation of pro-inflammatory cytokine release and 
adhesion molecule expression [114]. Additionally, chlamydial antigen (cHsp60) and LPS 
have been shown to induce the oxidation of LDL in the intima [115]. In the late phase of 
atherosclerosis, it is thought that macrophages can be stimulated by cHsp60 to secrete 
MMPs which weaken the plaque therefore contributing to the plaque destabilisation [116]. 
However, antibiotic treatment of patients to prevent a cardiac event had contradictory results 
in several clinical studies [111] and further clinical studies are necessary to define the exactly 
role of this pathogen in atherosclerosis.  
The Herpes family virus, including CMV, might also play a role in atherosclerosis; it 
has been shown that infection of ApoE-/- mice with this virus increased lesion formation [117]. 
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CMV has been detected in atherosclerotic plaques in humans [118], whereas a later report 
found CMV in atherosclerotic plaques and in non-atherosclerotic tissues, leading to the 
conclusion that CMV doesn’t play a direct causative role in the development of 
atherosclerosis [119]. Additionally, several association studies resulted in contradictory data 
regarding whether CMV is an important pathogen in atherosclerosis or not. Thus the role of 
CMV in the progression of atherosclerosis remains unclear. Since several pathogens have 
been found in atherosclerotic plaques, the concept arises that the total burden of pathogens 
might play a role in artherogenesis rather than a single pathogen. In a human association 
study it was found that several pathogens were associated with CAD. Further, the C-reactive 
protein level was correlated positively with increasing pathogen burden, suggesting that the 
intensity of the inflammatory response is related to the burden of pathogens [120].  
 
1.1.5 Macrophages in atherosclerosis 
 
Macrophages play a crucial role at all stages of atherosclerosis from early lesion 
formation to advance plaque progression [18]. The importance of these cells has been 
demonstrated in several studies. For example, ApoE-/- mice transplanted with bone marrow 
of CD11b-diphtheria toxin receptor (DTR) transgenic mice showed, following administration 
of diphtheria toxin that selectively kills monocytes/macrophages, reduced plaque progression 
and altered plaque contents including less collagen and necrotic core formation [121]. During 
lesion initiation, the activation of endothelial cells by several stimuli leads to the recruitment 
of monocytes, followed by their entry into the intima guided by chemoattractants or 
chemokines, where they differentiate into macrophages driven by M-CSF [78]. The 
differentiation is accompanied by the up-regulation of SRs and TLRs which are 
pattern-recognition receptors for innate immunity. As discussed before, the lipids in the 
intima undergo several modifications including oxidation, leading to an atherogenic form. The 
macrophages have been shown to be capable of oxidizing LDL in vitro and therefore may 
contribute to the modification process: They express 12/15-LOX, MPO, inducible nitric oxide 
synthase (iNOS) and NADPH oxidase, which are proposed to participate in the oxidation of 
LDL in vitro and which are detectable in atherosclerotic lesions [122].  
The scavenger receptors, notably the SR-A and CD36, mediate the uptake of oxLDL 
into macrophages leading to the accumulation of cholesterol within the cells. Beside their role 
in the uptake of oxLDL, the SRs’ trans-membrane receptors, which recognize polyanionic 
macromolecules, are involved in the phagocytosis of pathogens and apoptotic cells as well 
as in cell adhesion [123]. SR-A and CD36 are thought to be pro-atherogenic by mediating 
most of the oxLDL uptake as well as inducing pro-inflammatory gene expression and 
macrophage apoptosis. However, several animal studies have shown contradictory results 
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and do not answer the question of whether SR-A and CD36 promote the development of 
atherosclerosis or not [44-46].   
The toll-like receptors are single membrane-spanning and non-catalytic receptors 
which recognize molecules derived from microbes, and play a key role in the innate immune 
system. Human blood monocytes express several TLRs, mainly TLR 2 and 4. In 
atherosclerotic lesions, increased expression of TLR 1, 2 and 4 has been detected [124, 
125]. TLR 2 and 4 can promote lipid uptake in macrophages in vitro; an ApoE-/- experiment 
showed that they, in particular TLR 4, contribute to the intimal foam cell formation in the early 
state of atherosclerosis [126, 127]. On the other hand, deletion of TLR 7 in ApoE-/- mice 
accelerated lesion development and promoted a more vulnerable plaque phenotype; this 
atheroprotective role might be achieved by the shift of monocytes/macrophages toward an 
alternatively activated anti-inflammatory phenotype [128]. Hence, the TLRs seem to play a 
dual role in atherosclerosis as they show pro- and anti-atherosclerotic effects.  
A hallmark in atherosclerosis is the formation of macrophage “foam cells” which 
contain massive amounts of cholesterol esters [18]. Prolonged exposure to oxLDL results in 
the failure of the lipid handling mechanism of the cells such as the storage in droplets, 
β-oxidation and cholesterol efflux leading to a large accumulation of cholesterol within the 
cells, followed by lipotoxic injury, induction of pro-inflammatory cytokines release and 
eventually cell death [129]. Unrestricted uptake of oxLDL may occur because cholesterol 
from LDL inhibits the expression of the classical LDL receptor but does not reduce 
expression of SR. Modified lipids taken up by receptor-mediated endocytosis are delivered to 
lysosomes and other degradative organelles where their cholesterol ester is hydrolyzed to 
free cholesterol (FC) and fatty acids. To remove the excess FC, the reverse cholesterol 
transport takes place at the plasma membrane, the first step of this process being mediated 
by the ATP-binding cassette transporters A1 (ABCA1) and G1 (ABCG1) [129]. It has been 
shown that lack of both, ABCA1 and ABCG1 in LDLR-/- mice increased atherosclerosis and 
accumulation of myocardial foam cells [130]. In the absence of an acceptor (e.g. ApoA-1 in 
HDL), excess FC can be converted to cholesterol ester by the acyl-CoA cholesterol 
acyltransferase1 (ACAT1), and stored in the foam cell cytoplasm as lipid droplets. ACAT1 is 
expressed in human macrophages in atherosclerotic lesions and deficiency of this enzyme in 
ApoE-/- or LDLR-/- mice led to extensive storage of unesterified cholesterol in the skin and 
brain but did not prevent atherosclerosis [131]. Amongst the contribution to foam cell 
formation, FC can also induce directly apoptosis and the secretion of TNF-α as well as IL-6, 
thus participating in the necrotic core formation and in the inflammatory response of 
macrophages [129].    
In plaques susceptible to rupture, the volume of lipid content is increased and there is 
a shift toward a predominance of monocytes/macrophages compared to SMCs [132]. 
Moreover, the rupture has been thought to occur from vulnerable plaques which have been 
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defined as thin-cap fibroatheroma containing a necrotic core with a overlying thin fibrous cap 
(<65 mm) and infiltrated macrophages [25]. It is thought that macrophages are involved, 
through several mechanisms, in the changes of the plaque morphology and thus in the 
progression of atherosclerotic lesions. For example, it has been shown that macrophages 
can trigger apoptosis of SMCs in vitro [133] suggesting that they contribute to the necrotic 
core formation. Additionally, MMP or other serine proteases released from macrophages 
may participate in the thinning of the cap by degradation of extracellular matrix proteins [21]. 
Further, activation of macrophages in advanced plaques leads to the release of inflammatory 
cytokines, procoagulant/thrombotic factors, and vasoactive molecules such as NO and ROS 
which can destabilize the plaque [14].   
Monocytes originate from bone marrow-derived progenitor cells and can differentiate 
into several macrophage subsets including M1 and M2 macrophages. In response to some 
bacterial fragments such as LPS or the Th1 cytokine IFN-γ, macrophages differentiate into 
classically activated M1 macrophages. They mediate the defence of the body against a 
variety of bacteria, protozoa and viruses and have roles in anti-tumour immunity by 
production of pro-inflammatory cytokines as well as reactive nitrogen and oxygen 
intermediates. The alternative activated M2 macrophage phenotype can be obtained by 
glucocorticoids and transforming growth factor beta (TGF-β) as well as by IL-4, IL-13 and 
IL-10, which are released by Th2 cells. They exhibit anti-inflammatory functions and regulate 
wound healing. The M2 macrophages strongly express scavenger, mannose and galactose 
receptors, and have been shown to induce differentiation of regulatory T cells [134-136]. In 
young ApoE-/- mice, the lesion infiltrated macrophages presented an M2 phenotype, whereas 
in aged ApoE-/- mice the M1 phenotype appeared to become predominant [137]. Macrophage 
heterogeneity in the plaques has also been described in human atherosclerotic arteries. The 
M1 macrophages have been found mainly in the lipid core of the atherosclerotic lesions and 
the M2 macrophages in the shoulder region as well as in the periphery of the plaques [138, 
139]. It is thought that macrophage heterogeneity may play an important role in the 
progression and outcome of atherosclerosis and that an imbalance in the ratio M1/M2 might 
result in an impaired resolution of the inflammatory status [134]. 
 
1.1.6 Hypoxia and angiogenesis in atherosclerosis 
 
Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a 
crucial role in atherosclerosis, particularly in plaque destabilisation and lesion progression. In 
early stages of atherosclerosis, angiogenesis supports the growth and stabilisation of the 
plaques by providing them with oxygen and nutrients. Later, the formation of microvessels 
contributes to the recruitment of inflammatory cells and is associated with intraplaque 
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haemorrhage which occurs after the destruction of the endothelial layer of the microvessels. 
Thus, the formation of microvessels participates in the progression of an asymptomatic to a 
high risk unstable plaque [140, 141]. In a recent study in humans, it has been demonstrated 
that symptomatic patients had significantly more necrosis and plaque haemorrhage than 
asymptomatic patients, which was associated with increased VEGF expression [142]. 
Neovascularisation in ApoE-/- mice was associated with advanced atheromas, and inhibition 
of angiogenesis reduced neovascularisation and plaque growth [143].  
 One of the key factors in angiogenesis is the VEGF. VEGFs have a dual role in the 
cardiovascular system as their expression in the normal vessel is necessary to maintain the 
vascular homeostasis, whereas in atherosclerotic lesions it contributes to the inflammatory 
process, to intima thickening, and to intraplaque angiogenesis through induction of 
endothelial cell proliferation, migration, survival and vascular hyperpermeability [144, 145]. In 
animal models, administration of VEGF resulted in an increase of the plaque area as well as 
of the amount of plaque macrophages [146] and inhibition of VEGF expression reduced the 
progression to advanced atherosclerosis [147].   
The mechanisms which regulate angiogenesis are signalling pathways of hypoxia 
(reduced oxygen level), inflammation and ROS. It has been shown that the hypoxia-inducible 
factor 1 (HIF-1) regulates the expression of several angiogenic growth factors and acts as a 
main regulator of angiogenesis [148]. Chronic inflammation and angiogenesis in 
atherosclerosis are tightly linked. For example, the cytokine IL-1β, which is present in 
atherosclerotic lesions, up-regulated the expression of VEGF in rat aortic smooth muscle 
cells [149].  
Sluimer et al. demonstrated that hypoxia is present in human advanced 
atherosclerotic lesions by staining human carotid atherosclerotic plaques sections after the 
treatment of patients with pimonidazole, which is irreversibly metabolized in hypoxic cells 
only. They also showed that hypoxia correlates with the presence of macrophages, 
angiogenesis, thrombus formation and with the expression of HIF-1α, HIF-2α and VEGF 
[150]. In a recent publication, hypoxic areas were identified in atherosclerotic plaques of 
ApoE-/- mice and altered lipid metabolism was observed in hypoxic mouse macrophages 
leading to an increased sterol content by induction of sterol synthesis and suppression of 
cholesterol efflux [151]. In vitro, hypoxia increased cytokine production [152], LDL oxidation 
[153], lipid loading [154], and HIF-1α and HIF-2α expression [155] in human macrophages.  
All these findings lead to the conclusion that hypoxia may promote lesion progression by 
enhancing lipid accumulation and through an increase in inflammation and angiogenesis 
[156].   
Hypoxia activates gene expression which allows an adaption to the hypoxia induced 
stress condition through oxygen-sensitive transcription factors including HIF. HIFs consist of 
α/β-heterodimers and include HIF-1β and the three oxygen-sensitive mammalian subunits 
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HIF-1α, HIF-2α and HIF-3α. HIF-1β is constitutively expressed in the nucleus and is not 
affected by hypoxia. HIF-1α is the most ubiquitously expressed and best characterized of the 
family and is thought to be the master regulator of hypoxic response [157]. HIF-2α has a 
similar regulation as HIF-1α but exhibits a different expression pattern restricted to certain 
cell types [158]. HIF-3α is less well characterized and might act as an internal repressor of 
the HIF system [159]. Under normoxic conditions, the HIF-1α protein is hydroxylated by prolyl 
hydroxylases and degraded by ubiquitination and proteasomal degradation. In contrast, 
under hypoxia the prolyl hydroxylases are inactive and does not hydroxylate HIF-1α; as a 
result, the HIF-1α accumulates, translocates to the nucleus and becomes active by 
heterodimerization with HIF-1β subunits. In the nucleus, the heterodimers bind to hypoxia 
responsive elements on the promoter of target genes and induce gene expression [160-163]. 
HIF-1 regulates the expression of genes involved in a wide spectrum of cellular responses 
including angiogenesis, vascular reactivity and remodelling, vasomotor control, glucose and 
energy metabolism, erythropoiesis, iron homeostasis and metal transport, pH regulation, cell 
proliferation and viability, and nucleotide metabolism [164].  
In atherosclerosis, it has been shown that HIF-1α expression correlates with an 
advanced plaque phenotype with abundant inflammation and VEGF expression. HIF-1α has 
been found to be localized in the shoulder and cap areas of plaques as well as between the 
atheromatous lipid core and the media. The expression was predominately detected in 
macrophages, foam cells and less in SMCs.  Additionally, a strong association between the 
level of HIF-1α and VEGF protein has been shown, suggesting that HIF-1α is active in 
atherosclerotic lesions. In a human study it was shown that hypoxia co-localizes and 
correlates with HIF-1α, HIF-2α and VEGF, and that HIF-1α and HIF-2α strongly correlate with 
macrophage-specific immunoreactivity in atherosclerotic plaques [150]. Non-hypoxic 
activation of macrophages in vitro by the pro-inflammatory stimuli LPS induced the 
expression of HIF-1α, suggesting an additional inflammatory regulation mechanism of HIF-1α 
[165]. As described before, macrophages can be polarized into different types, the M1 and 
M2 macrophages. In atherosclerotic plaques both types are expressed although they differ in 
the preference location within the plaques [139]. In vitro differentiation of mouse 
macrophages revealed that HIF-α isoforms are differentially expressed in different polarized 
macrophages; HIF-1α has been shown to be exclusively expressed in M1 polarized 
macrophages whereas HIF-2α was abundant in M2 polarized macrophages [166]. This 
reveals that the two transcription factors, HIF-1α and HIF-2α might have physiologically 
different functions as there is evidence that M1 macrophages exhibit pro-inflammatory and 
M2 macrophages anti-inflammatory functions. However, the situation in atherosclerotic 
plaque is complex and it is thought that heterogeneity rather than the simple M1 and M2 
macrophages or HIF-1α and HIF-2α paradigm might be reality.  
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 1.2 Lipoxygenases: lipid peroxidising enzymes  
 
Lipoxygenases form a heterogeneous family of non-heme iron-containing dioxygenases 
which regio- and stereo-specifically catalyse the insertion of molecular oxygen into 
polyunsaturated fatty acids. The reaction leads to the formation of the corresponding 
hydroperoxy derivatives which can be further metabolized to various lipid mediators such as 
hydroxyeicosatetraenoic acids (HETEs), leukotrienes, lipoxins, maresins and hepoxilins. The 
substrate specificity differs between the LOXs and some of the LOXs do not only accept free 
fatty acid but also ester lipids incorporated in biomembranes and lipoproteins [167]. Although 
the detailed mechanism of the LOX reaction is still under investigation the radical nature of 
the reaction is the most accepted hypothesis consisting of the following three steps (Fig. 3) 
[168]:   
 
i) stereo-selective hydrogen abstraction from a double allelic methylene group 
ii) radical rearrangement (+2 and -2) which is accompanied by a Z, E-diene 
conjugation 
iii) stereo-specific (S- or R-) insertion of molecular dioxygen, and reduction of the 
hydroperoxy radical intermediate to the corresponding anion 
 
 
  
Figure 3: Radical mechanism of the lipoxygenase reaction [168]. 
 
1.2.1 Lipoxygenases family 
 
LOXs are widely distributed in mammals and plants and the first investigations of 
these enzymes were performed in soybean LOX-1 and other plant isoenzymes. In 1974, the 
30 
 
lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE, 12-HETE) was 
detected in human thrombocytes following incubation with exogenous arachidonic acid [169]. 
Since then, 22 different LOX sequences have been found in mammals and Fürstenberg et al. 
created a phylogentic tree based on DNA sequence data; these divided the LOXs into 5 
groups: the platelet-type 12S-LOX, 15/12S-LOX, epidermis-type 12S-LOX, 5S-LOX and 
epidermis-type LOX (Fig.4) [170]. The nomenclature is based on the position of oxygen 
insertion (at carbon 3, 5, 8, 12 or 15) and stereo-configuration (R or S) of the resulting HETE 
product. In humans, six members of these genes have been described, the epidermis-type 
LOX-3 (ALOX3), the 5(S)-LOX (ALOX5), the platelet-type 12(S)-LOX (ALOX12), the 
epidermis-type 12(R)-LOX (ALOX12B), the reticulocyte-type 15(S)-LOX-1 (ALOX15) and the 
epidermis-type 15(S)-LOX-2 (ALOX15B). In this thesis, the term ALOX will be used to 
describe the different LOXs.  
 
 
 
Figure 4: Phylogenetic tree of mammalian LOXs which divides the LOXs into 5 groups: the platelet-
type 12S-LOX, 15/12S-LOX, epidermis-type 12S-LOX, 5S-LOX and epidermis-type LOX [170]. 
 
1.2.2 12/15-Lipoxygenases  
 
The term 12/15-lipoxygenases refers to the similarity of the human ALOX12 and the 
human ALOX15 which can form similar products from common substrates. 12/15-LOXs 
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oxidize the substrate at the carbon atoms 12 and 15 and have high substrate specificity, 
metabolizing mainly arachidonic acid and linoleic acid [171]. ALOX15 can not only 
metabolize free polyunsaturated fatty acids such as arachidonic acid and linoleic acids but 
also complex lipid esters even when incorporated in membranes or lipoproteins [172].  
One of the main substrates, arachidonic acid, can be converted into lipid 
hydroperoxides (hydroxyperoxy-eicosatetraenoic acids, HPETEs) by different ALOX isoforms 
which can be rapidly reduced intracellularly into their corresponding hydroxides 
(hydroxyeicosatetraenoic acids, HETEs) or metabolized to other classes of secondary lipid 
mediators such as lipoxins, hepoxilins and trioxilins. The other main substrate, linoleic acid, 
can be metabolized by ALOX15 and ALOX12B leading to the generation of 
13(S)-hydroperoxyoctadecadienic acid (13(S)-HPODE, 13-HPODE) which is peroxidized to 
13(S)-hydroxyoctadecadienoic acid (13-(S)-HODE, 13-HODE). The omega-3-fatty acid, 
docosahexanoic acid (DHA), is another substrate for ALOX15 and can be metabolized into 
an epoxy intermediate followed by the generation of, for example, resolvin D1 and protectin 
D1. The positional specificity varies between the isoforms, for example ALOX15 can 
oxygenate arachidonic acid at carbon atom 12 or 15 leading to the formation of their 
corresponding HPETEs. ALOX15B, which has as its main substrate arachidonic acid, 
selectively inserts the oxygen at carbon15 to produce 15-HPETE (Fig. 5) [173]. 
 
 
Figure 5: Major 12- and 15-lipoxygenase isoforms and their lipid substrates and products [173]. 
 
 
 12/15-LOX isoenzymes have a different expression pattern in different animals, for 
example, mice only express a leukocyte-type 12-LOX [174] while human only express a 
reticulocyte-type 15-LOX. In rabbits, a reticulocyte-type 15-LOX and a leukocyte-type 
12-LOX are expressed. These discrepancies should be considered when different animal 
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models are used to study atherosclerosis. The different 12/15-LOX isoenzymes can produce 
different metabolites and different amounts of these metabolites which could cause diverse 
effects on atherosclerosis [171].  
The crystal structure of the rabbit ALOX15 has been solved and shows that this 
enzyme consists of a single polypeptide chain which is folded into a two-domain structure; a 
catalytic and an N-terminal β-barrel domain connected to each other by several helices. The 
C-terminal catalytic helical domain contains the catalytic non-heme, non-sulfur-bound iron 
cluster whereas the N-terminal domain is implicated in the membrane binding of various 
ALOXs isoforms [175].  
 
1.2.3 ALOX15B 
 
In 1997, Brash et al. discovered a second 15(S)-lipoxygenase in humans by 
investigation of cDNAs cloned from human hair roots. They found that this new 
15(S)-lipoxygenase has about 40% amino acid sequence similarity to the human ALOX15. 
The sequence contains the absolutely conserved histidines (494, 499, 504, 522, 531 and 690 
in soybean L1) and the C-terminal isoleucine (Ile839 in soybean L1) [176]. The H499, H504, 
H690 and Ile 839 have been described to be required for iron binding in the soybean L1 
enzyme [177]. The newly found 15(S)-lipoxygenase differs from the other members of the 
family in the putative fifth iron ligand which is serine (S558), compared to histidine (H544) in 
the reticulocyte 15-lipoxygenase, or asparagine (N693) in the soybean L1 enzyme. Another 
difference is the catalytic activity, as it oxygenates more exclusively arachidonic acid at the 
15 carbon, while the linoleic acid is a relatively poor substrate [178]. This novel human 
lipoxygenase has been termed epidermis-type 15-LOX-2, 15-lipoxygenase 2 and ALOX15B. 
At the same time, a mouse 8(S)-lipoxygenase has been identified which shares 78% 
sequence identity to the human ALOX15B protein and is therefore considered to be its 
mouse homologue [170, 179].  
In 2012, Arora et al. published the three dimensional structure of the ALOX15B 
protein based on available homologous template structures in protein structure data bank 
resources. The protein is predicted to consist of two domains: a small N-terminal domain 
containing the polycystein-1, lipoxygenase, alpha-toxin (PLAT) domain, which is totally 
arranged with β-sheets (cyan), and a major C-terminal catalytic domain with α-β fold type, 
which is mainly composed of α-helices (red) and contains the active side (blue) (Fig.6). 
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Figure 6: Modeled structure of arachidonate 15-lipoxygenase 2, cyan: small N-terminal domain 
containing the polycystein-1, lipoxygenase, alpha-toxin (PLAT) domain, red: major C-terminal catalytic 
domain, blue: active side [180]. 
 
Brash et al. investigated the ALOX15B mRNA level in different tissues and detected 
its location in four tissues: skin, lung, prostate and cornea [178]. In human corneal 
epithelium, ALOX15B is predominant and investigations of the subcellular localization of the 
two 15-LOX revealed that ALOX15B was located in the cytoplasm and in the nucleus, 
whereas the ALOX15 protein was only detected in the cytoplasm [181]. In normal prostate 
cells, ALOX15B is the major expressed 15-LOX but is decreased or lost in prostate cancer 
cells in vivo [182]. The study of the subcellular distribution of ALOX15B in normal human 
prostate epithelial cells showed that this enzyme is expressed at multiple locations including 
the cytoplasm, cytoskeleton, cell-cell border and nucleus [183].  
Besides the first described tissue distribution, ALOX15B expression has been found 
in several other tissues including normal esophageal epithelial cells [184], primary ovarian 
carcinoma [185], in normal mammary epithelial cells [186] and in benign cutaneous 
sebaceous glands [187]. In contrast, ALOX15B expression is down-regulated in prostate 
cancer, benign and neoplastic sebaceous glands, esophageal cancer and lung cancer. 
The originally cloned full length ALOX15B gene (Ref.SeqGene: NG_029482.1) is 
located at 17p13.1 and consists of 14 exons. The cDNA encodes for 676 amino acids with an 
approximately molecular mass of 76 kDa. Six splice variants have been cloned, 
characterized and termed ALOX15B-sv-a (15-LOX-2-sv-a) to ALOX15B-sv-f (15-LOX-2-sv-f) 
[182, 188]. ALOX15B-sv-a lacks exon 9 which leads to the removal of a complete α-helix 
from the substrate-binding pocket causing a reduced activity in metabolizing arachidonic acid 
[189]. The three splice variants ALOX15B-sv-a/b/c are mainly found outside of the nucleus. 
This effect has been partially explained by the detection of a potential bi-partite nuclear 
signal (NLS) in the N-terminus of ALOX15B lacking in these splice variants. 
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The ALOX15B promoter is TATA-less and has four potential Sp1 sites including 
GC-boxes and CACCC-boxes located in the proximal promoter. Tang et al. showed that the 
transcription factors Sp1 positively and Sp3 negatively regulate ALOX15B gene expression 
in normal human prostate cells [190]. Sp1 is thought to be responsible for the recruitment of 
TATA-binding protein and for the fixation of the transcription start site (TSS) on TATA-less 
promoters [188].  
Besides the transcription factors Sp1 and Sp3, several regulatory mechanisms have 
been described for ALOX15B expression. For example, hypoxia has been shown to induce 
the expression of ALOX15B in human primary macrophages [153] as well as in rabbit 
pulmonary artery smooth muscle cells [191]. In vitro treatment of human macrophages with 
the HIF-1α stabilizer dimethyloxalylglycine (DMOG) led to an increased ALOX15B 
expression, and knocking down of HIF-1α decreased the production of the ALOX15B 
metabolite, 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE, 15-HETE), suggesting that 
HIF-1α might modulate ALOX15B enzyme activity [192]. In normal human epidermal 
keratinocytes, ALOX15B mRNA and protein expression was enhanced after stimulation with 
IFN-γ in vitro [193]. Subbarayan et al. found that the ALOX15B product, 15-HETE, is an 
endogenous ligand for the peroxisome proliferator-activated receptor gamma (PPAR-γ) and 
provides a negative feedback mechanism in the regulation of ALOX15B. The ligand-activated 
nuclear receptor PPAR-γ can interact with the ALOX15B gene through a nuclear 
receptor-binding half-site (AGGTCA); this overlaps with a putative CRE (TGAGGTCA) 
element and subsequently suppresses the ALOX15B expression [194]. This inverse 
relationship between PPAR-γ and ALOX15B has been described in many normal and their 
corresponding tumour epithelia, incl. prostate, breast, oesophageal, lung and bladder 
epithelia [195] indicating that PPAR-γ might be a major regulator of ALOX15B expression. 
Feng et al. discovered a glucocorticoid receptor responsive element in the ALOX15B 
promoter; over-expression of the glucocorticoid receptor, a well-known transcription factor, 
also led to down-regulation of the ALOX15B promoter activity [196]. 
 
1.2.4 The biological implications of 12/15-lipoxygenases 
 
The main biological implications of 12/15-LOXs are thought to be cell differentiation, 
inflammation, apoptosis and angiogenesis. Broad evidence shows that the polyunsaturated 
fatty acids, their lipid metabolites and enzymes, and the 12/15-LOX pathways are involved in 
the regulation of various homeostatic processes. Hence, they also participate in the 
pathogenesis of diseases including diabetes, atherosclerosis, renal disease and obesity, as 
well as various diseases of the central and peripheral nervous systems such as Alzheimer’s 
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and Parkinson’s disease [173, 197]. In this section, the main biological implications and 
some of the related diseases will be discussed. 
 
Cell differentiation 
The first mammalian 15-LOX detected in rabbit reticulocytes showed the capability to 
inhibit cellular respiration by lysis of intact mitochondria [198]. Reticulocytes are precursors of 
the mature red blood cells, the erythrocytes. One of the crucial processes in the maturation 
of reticulocytes is the degradation of organelles, mainly mitochondria. In vitro studies of 
rabbit reticulocytes revealed that the presence of 15-LOX is associated with the onset of 
mitochondrial degradation. However, enzymatic inhibition of 15-LOX delayed but did not 
block this process, suggesting that other metabolic systems are involved in the mitochondrial 
degradation process leading to the differentiation of erythrocytes [199, 200].  
12/15-LOX might be involved in the differentiation of other cell types, for example 
tracheobronchial cells and osteoclasts. Human tracheobronchial cells grown in air interface 
culture differentiate to form a mucociliary epithelium in the presence of retinoic acid. In this 
process, the expression of ALOX15 has been found to be turned on in the late phases of 
mucous differentiation [201]. Another example is the osteoclasts differentiation, cells which 
are responsible for bone resorption and homeostasis of bony tissue [202]. The ALOX12/15 
gene has been identified as a negative regulator of bone mass density and experiments in 
12/15-LOX knockout mice revealed that this enzyme influences the skeletal development 
[203]. In vitro, the addition of 12- and 15-HETE to osteoclast precursors led to an increased 
maturation of these cells suggesting that 12/15-LOX is a positive regulator of osteoclast 
development. In vivo, enzymatic inhibition as well as deletion of 12/15-LOX in mice led to 
significantly reduced osteoclastogenesis [204].  
ALOX15B expression and 15-HETE level are decreased in human prostate 
carcinoma [187]. Bathia et al. found that ALOX15B and its splice variants ALOX15B-sv-b 
have tumour suppressing functions in vivo independent from their arachidonic acid 
oxygenating activity. The suppression was associated with an ability to induce cell 
senescence [183]. These data have been corroborated by Tang et al. who found increased 
ALOX15B expression in senescent normal human prostate epithelial cells, and that treatment 
with 15-HETE induced a senescence-like phenotype in normal human prostate epithelial 
cells [188]. Additionally, the prostate specific over-expression of ALOX15B in mice led to 
hyperplasia of the prostate as well as to an induction of cell senescence. As cell senescence 
is a strong suppressor of tumour progression from hyperplastic lesions, ALOX15B might 
function as a barrier for tumour development [205].  
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Inflammation 
There is evidence from several studies that 12/15-LOX and its products have both 
pro- and anti-inflammatory effects. It is thought that these enzymes are involved in the 
pathogenesis of multiple inflammatory diseases, including renal diseases, diabetes, arthritis, 
asthma, intestinal diseases and cardiovascular diseases [71, 206]. The metabolites of 
12/15-LOX, the 12-HETE and 15-HETE as well as 13-HODE, have been shown to modulate 
the activity of several intracellular signalling pathways including Ras, CREB, protein kinase 
C, MAP kinases and the NF-κB pathway [206]. For example, 13-HPODE induced the 
transcription of inflammatory genes in vascular smooth muscle cells (VSMCs) via the NF-κB 
pathway [207]. On the other hand, 15-HETE and 13-HODE have been shown to regulate the 
activity of PPAR-γ which has been reported to be involved in fat and glucose metabolism, 
and have also shown anti-inflammatory activity in several mice models with acute and 
chronic inflammation [208]. Additionally, 15-HETE indicated several anti-inflammatory effects 
in vitro, for example the blocking of polymorphonuclear neutrophils (PMNs) migration across 
cytokine activated endothelium [209], or inhibiting LTB4 induced chemotaxis [210] of human 
neutrophils and superoxide anion generation [211]. 
The arachidonic acid derivate 15-HETE can be further metabolized by 5-LOX into 
lipoxin A4 and B4. The lipoxins have been shown to exhibit anti-inflammatory and 
pro-resolving properties such as the arrest of LTB4 induced chemotaxis of neutrophils [212] 
and transmigration through endothelial cells [213]. Another capability of the lipoxins is the 
stimulation of the uptake of apoptotic cells by macrophages which is a crucial step in the 
resolution phase of inflammation [214]. The failure of the resolution of inflammation can 
promote chronic inflammatory diseases. For example, in a mouse model of arthritis, the 
deficiency of 12/15-LOX led to increased inflammatory gene expression and to reduced 
levels of lipoxin A4 in the inflamed synovia, accompanied by an exacerbated inflammation 
and enhanced inflammatory tissue damage [215]. In another experiment, administration of 
stable lipoxin A4 analogue to a murine model of asthma resulted in the inhibition of airway 
hyper-responsiveness and allergic airway inflammation [216]. 
12/15-LOX has been recently reported to participate in the metabolism of the long 
chain omega-3 fatty acid, DHA [217]. DHA can be metabolized into an epoxy intermediate 
followed by the generation of resolvin D1 and protectin D1. The resolvins possess potent 
anti-inflammatory effects including reducing neutrophil traffic, regulating cytokine and ROS 
release of neutrophils, and lowering the severity of the inflammatory response. The 
protectins have anti-apoptotic and anti-inflammatory effects and are thought to play a 
particular protective role in neural systems, stroke and Alzheimer disease [71, 218]. Merched 
et al. investigated the 12/15-LOX derived lipid mediators in the context of atherosclerosis and 
found that lipoxin A4, resolvin D1 and protectin D1 suppressed pro-inflammatory cytokine 
production by macrophages and stimulate phagocytic activity of macrophages toward 
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apoptotic cells. They suggested that these pro-resolving mediators might play an important 
role in the control of local inflammation and in the development of atherosclerosis [219].    
The second 15-lipoxygenase has been shown to be implicated in psoriasis, an 
inflammatory skin disease. In the living layer of psoriatic lesions, a strong expression of 
ALOX15B was observed and after intralesional injection of the ALOX15B metabolite 
15-HETE, the symptoms of psoriasis vulgaris were improved in humans [220]. Since IFN-γ 
has been reported to be an important cytokine in the development of psoriasis, IFN-γ might 
be the trigger for the anti-inflammatory and anti-proliferative mechanism via induction of 
ALOX15B expression in human skin [193].  
In contrast, a pro-inflammatory role of 12/15-LOX has been described in vitro and in 
vivo. For example, a link between the 12/15-LOX pathway and diabetes mellitus with 
involvement of inflammatory mechanisms has been established by several studies. The 
12/15-LOX metabolite 12-HETE was elevated in the urine of patients with diabetes with 
normal renal function as well as with micro- and macroalbuminuria [221]. Mice lacking 
12/15-LOX when fed a high fat diet were protected from insulin resistance in liver, muscle 
and adipose tissue, probably due to the suppression of the pro-inflammatory macrophage 
infiltration and inflammatory cytokine production by 12/15-LOX in adipose tissue [222]. In line 
with this, Chakrabarti et al. found that 12/15-LOX mRNA was highly elevated in white 
epididymal adipocytes of high fat fed mice and addition of the 12/15-LOX products, 12-HETE 
and 12-HPETE, to adipocytes in vitro resulted in an increased expression of pro-
inflammatory cytokines such as IL-6, TNF-α and MCP-1 and in an impaired insulin signalling, 
suggesting that 12/15-LOX promotes inflammation and insulin resistance in combination with 
obesity [223].  
 
Apoptosis 
Apoptosis is the process of programmed cell death; defects in this mechanism have 
been reported to be involved in a variety of diseases. Excessive apoptosis causes atrophy 
and insufficient apoptosis results in uncontrolled cell proliferation which can lead to tumour 
development. The 12/15-LOXs and their products play a role in carcinogenesis by regulating 
several biological processes including cell growth, apoptosis and angiogenesis. In general, 
platelet-type ALOX12 has been considered to be pro-carcinogenic while ALOX15B is thought 
to suppress carcinogenesis. The role of ALOX15 that has been described so far is 
controversial.  
In several studies, it has been shown that many tumour tissues over-express ALOX12 
and produce 12-HETE. Furthermore, inhibition of ALOX12 has been shown to induce 
apoptosis in a variety of cancer cells including breast [224], gastric [225], lung [226], prostate 
[227] and ovarian [228] cancer cells. Multiple mechanisms are thought to be responsible for 
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the apoptotic effect of ALOX12 inhibition. For example in breast cancer cells, an association 
between ALOX12 inhibition and a reduced level of anti-apoptotic protein Bcl-2 and Mcl-1 has 
been observed, indicating a pro-carcinogenic role for ALOX12 [224]. In ovarian cancer cell 
lines, reduction of the ALOX12 protein level led to a decreased cell growth and survival 
presumably via MAPK signalling pathway [228]. 
The role of ALOX15 in carcinogenesis has been studied in colorectal, prostate, lung 
and breast cancer. Shureiqi et al. investigated in vivo tissue of colorectal cancer and reported 
a significantly decreased ALOX15 expression as well as a lower level of its product 
13-HODE compared to normal tissue [229]. Studies of the mechanisms of ALOX15 in 
colorectal cancer revealed that loss of proliferation, induction of terminal differentiation and 
apoptosis as well as decreased motility, invasion and migration of colorectal cancer cells are 
responsible for the tumour suppressive effect of ALOX15. An example for the pro-apoptotic 
pathway has been described by Cimen et al. They found that ALOX15 exhibits the 
anti-tumourigenic activity by inhibiting the anti-apoptotic inflammatory transcription factor 
NF-κB via the activation of PPAR-y, which is in turn a target of 13-HODE [230].   
On the other hand, an anti-apoptotic effect of ALOX15 has been described. For 
example, in pulmonary arteries of neonatal rats, hypoxia induced the formation of 15-HETE 
through stimulation of ALOX15 [231]. One mechanism responsible for the 15-HETE inhibited 
apoptosis in pulmonary artery smooth muscle cells (PASMCs) was reported to be mediated 
partly by inactivating K+-channels which are well-known inductors of apoptosis in PASMCs 
[232]. In addition, several other pathways have been reported to be involved in the 15-HETE 
mediated anti-apoptotic effect in PASMCs including the heat shock protein HSP90 [233], 
iNOS [234], Erk 1/2 [235] and the PI3K/Akt pathway [236].  
There is indication that ALOX15B may have a pro-apoptotic effect, for example in 
head and neck carcinoma: ALOX15B expression and activity was reduced in head an neck 
carcinoma (HNC) [237], and radiation induced up-regulation of ALOX15B in HNC resulted in 
a significant induction of apoptosis [238].  
 
Angiogenesis 
There is evidence that the 12/15-LOX pathway is involved in vascular, retinal and 
tumour angiogenesis. Multiple animal and human studies have indicated a dual role with both 
pro- and anti-angiogenic activities. For example, the over-expression of ALOX15 in human 
prostate cancer epithelial cells in vitro caused cell proliferation and increased angiogenesis 
[239]. Additionally, the lipoxygenase metabolites 5(S)-hydroxyeicosatetraenoic acid 
(5(S)-HETE, 5-HETE), 12-HETE and 15-HETE, have been shown to induce tube formation 
and migration in human dermal microvascular endothelial cells and to stimulate angiogenesis 
in vivo [240]. In contrast, angiogenesis was affected and tumour growth development was 
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inhibited in transgenic mice over-expressing 12/15-LOX in two different cancer models [241]. 
Lipoxin A4 (LXA4) seems to be a key metabolite of the anti-angiogenic effect; in a model of 
injury induced corneal revascularization, topical treatment with LXA4 reduced VEGF-A and 
vascular endothelial growth factor receptor-3 (VEGFR-3) expression, as well as inflammatory 
angiogenesis; furthermore deletion of 12/15-LOX in mice diminished the excess formation of 
angiogenesis [242]. Reduced VEGF-A expression was also observed in prostate cancer cells 
with restored ALOX15B expression suggesting that ALOX15B might induce tumour 
dormancy partly by suppression of VEGF expression [243].  
  
1.2.5 12/15-LOX in atherosclerosis 
 
Twenty years ago, research in experimental atherosclerosis revealed that ALOX15 is 
expressed in early lesions and co-localizes with epitopes of oxLDL in macrophage-rich 
regions [244, 245] as well as in human fatty streaks and more advanced atherosclerotic 
lesions [246]. However, these data have recently been questioned by Gertow et al. who 
found that ALOX15B is the main 12/15-LOX expressed in human carotid lesion and that its 
expression is higher in symptomatic compared to asymptomatic lesions. In contrast, ALOX15 
was only detected on a very low level [247]. In addition, different HETEs including 5-, 9-, 8-, 
11-, 12-, and 15-HETE have been detected in atherosclerotic plaques. The level of total 
HETEs was elevated in tissue samples from symptomatic compared to asymptomatic 
patients [248]. However these data were questioned by the findings of Waddington et al. who 
did not find an association of the fatty acid oxidation products with plaque instability and the 
incidence of symptomatic cerebrovascular disease. Their analysis of the chirality of the 
12/15-LOX products revealed that the linoleic acid products (HODE) and the arachidonic acid 
products (HETE) derived from non-enzymatic lipid peroxidation [249].   
The role of ALOX15 in atherogenesis remains controversial [171]. On the one hand 
there is evidence of a pro-atherogenic effect including direct contribution to the oxidation of 
LDL in vitro [167], up-regulation of the oxLDL receptor CD36 via PPAR-y by 15-HETE and 
13-HODE [250], and stimulation of VSMCs migration [251]. Moreover, 12-HETE has been 
shown to increase the monocyte adhesion to human endothelial cells and to mediate growth 
factor-induced proliferation, migration and gene expression in VSMCs in vitro [252].  In vivo, 
over-expression of 12/15-LOX in mice led to spontaneous formation of fatty streak lesions 
and to an increased monocyte adhesion to the endothelium, partly through molecular 
regulation of endothelial adhesion molecules expression [253]. There is also a relationship 
between 12/15-LOX and angiotensin II, a peptid hormone which causes vasoconstriction and 
hypertension. Several studies support this correlation. For example, the expression of 
ALOX12 protein in platelets and 12-HETE levels were increased in patients with essential 
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hypertension [254]. It was shown that angiotensin II directly up-regulates the expression and 
activity of ALOX15 in human aortic smooth muscle cells and macrophages in vitro [255]. In 
addition, angiotensin II induced monocyte adhesion to VSMCs [256] and increased the 
macrophage-mediated oxidation of LDL [257].  Hence, ALOX15 seems to be involved in 
angiotensin II mediated effects in the early steps of atherogenesis, through monocyte 
adhesion and oxidation of LDL. 
  On the other hand there is evidence of an atheroprotective effect of 12/15-LOX 
including the contribution to the resolution of inflammation resulting from the production of 
anti-inflammatory metabolites such as lipoxins, and from the anti-atherogenic effects of the 
metabolites 15-HETE and 13-HODE. For example, the arachidonic acid metabolite 15-HETE 
has been shown to inhibit the production of superoxide and the degranulation of PMNs 
following stimulation with LTB4 and platelet-activator factor [258]. In addition, 15-HETE also 
inhibited LTB4 induced chemotaxis [210] and endothelial transmigration of neutrophils [209] 
in vitro. The linoleic acid metabolite 13-HODE has been shown to be produced by endothelial 
cells as a chemorepellent contributing to the thrombo-resistance of the vessel wall under 
healthy conditions [259]. Furthermore, Kämmerer et al. found that 13-HODE stimulates the 
removal of cholesterol from mouse macrophages in vitro suggesting an anti-atherogenic role 
for 13-HODE [260].  
Animal models have not answered the question of whether ALOX15 is pro- or 
anti-atherogenic. Pro-atherogenic effects have been observed in several studies. 
Over-expression of human 15-lipoxygenase in the vascular wall led to an enhanced 
atherogenesis in LDLR-/- mice [261]. Knockout of 12/15-LOX in apoE deficient mice reduced 
lesion development as well as decreased formation of antibodies against oxLDL epitopes 
[262]. Depletion of 12/15-LOX in macrophages protected apoE-/- mice fed a western diet from 
atherosclerosis [263]. 12/15-LOX LDL receptor double knockout mice fed a PUFA-enriched 
diet had decreased plasma and liver lipid levels as well as decreased aortic atherosclerosis, 
suggesting that macrophage 12/15-LOX, in the context of dietary PUFA enrichment, 
adversely affects plasma and hepatic lipid metabolism [264].  
On the other hand, anti-atherogenic effects have also been observed. Specific 
over-expression of 15-LOX in macrophages of Watanabe heritable hyperlipidemic rabbits 
and the systemic over-expression of 15-LOX in New Zealand white rabbits was shown to 
protect from lipid deposition in the vessel wall during early atherosclerosis [265, 266]. 
Additionally, there are mouse studies showing an atheroprotective effect of the 12/15-LOXs. 
Merched et al. showed that expression of this enzyme protects against atherosclerosis in 
apoE mice with either global leukocyte 12/15-LOX deficiency, or with macrophage-specific 
over-expression of 12/15-LOX. These studies suggested that the production of the 
pro-resolving lipid mediators, namely lipoxins, resolvins and protectins, play a role in this 
atheroprotective effect [219]. 
41 
 
To solve the question of whether the 12/15-LOX activity is pro- or anti-atherogenic in 
humans, genetic association studies have been performed. In these studies, two rare 
functional polymorphisms in the ALOX15 gene have been investigated for their association 
with CAD and MI. The polymorphism in the promoter at position 292 (c.-292C>T) which leads 
to an increased enzyme activity showed a trend towards an atheroprotective effect in a small 
case control study for CAD [267, 268]. Another rare polymorphism in the coding region 
(T560M) that results in a drastically reduced enzyme activity was associated with a 
significantly increased risk of CAD in the ADVANCE study [269]. However, the investigation 
of functional variants in ALOX15 did not show a consistent association with clinical end 
points of atherosclerosis [270]. This might be due to the low frequency of the functional 
variants which would result in lack of power, or alternatively due to the redundancy of 
12/15-LOX activity in human macrophages. 
Interestingly, ALOX15B has been shown to be expressed in human macrophages 
and atherosclerotic plaques [153]. A recent study revealed that ALOX15B is the most 
abundant 12/15-LOX expressed in carotid lesions and that it is even associated with 
cerebrovascular symptoms [247]. In addition, Magnusson et al. demonstrated that silencing 
the ALOX15B gene in human macrophages decreased cellular lipid accumulation and 
reduced pro-inflammatory cytokine secretion in vitro [271]. Additionally, hypoxia, an important 
characteristic of atherosclerotic plaques and claimed to be pro-atherogenic [150], induced 
the expression of ALOX15B in human macrophages [153]. Knockdown of the mouse 
ALOX15B homologue, also known as ALOX8, in LDL receptor deficient mice, led to 
decreased subendothelial lipid accumulation in aortas, and reduced plaque T cell content 
and plasma level of IL-2 [271]. So far, ALOX15B seems to play a pro-atherogenic role in the 
development of atherosclerosis in cell culture and in mouse models but whether this enzyme 
is pro- or anti-atherogenic in humans is still unclear. To address this, I aimed in this thesis to 
investigate the regulation of the expression of different 12/15-LOXs in human macrophages 
and to analyse the association of polymorphisms in the ALOX15B gene with CAD in a small 
case control study. 
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Abstract 
 
Background: Atherosclerosis is a multifactorial disease and the underlying cause of 
coronary artery disease (CAD), myocardial infarction and stroke. Two main features are 
involved in the progression of atherosclerosis, lipid retention and inflammation. 
12/15-lipoxygenases are involved in inflammation and have been implicated in 
atherosclerosis. Genetic association studies of the 15-lipoxygenase 1 (ALOX15) in humans 
revealed a neutral to atheroprotective role of the enzyme. However, recently the 
epidermis-type 15-lipoxygenase 2 (ALOX15B) has been identified as the second 
15-lipoxygenase in human atherosclerotic plaques but its role in human atherosclerosis is 
still unclear.  
Methods: We screened the ALOX15B gene for polymorphisms and investigated the 
association of 18 detected polymorphisms with angiographically documented CAD in a case 
control study (n=496). In addition, we measured in vitro the enzyme activity and 
Michaelis-Menten kinetics of the detected non-synonymous polymorphic variants 
p.Arg486His (c.1457G>A), p.Gln656Arg (c.1967A>G) and p.Ile676Val (c.2026A>G).  
Results: We found that the linked polymorphisms at position c.1458-38G>C, c.1579+71C>T 
and c.1656G>A are associated with CAD (OR: 0.51 (0.27-0.94), p-value: 0.03). In addition, 
we show that the activity and the kinetics of the three non-synonymous ALOX15B enzyme 
variants (p.Arg486His, p.Gln656Arg and p.Ile676Val) do not differ from the wild-type enzyme.  
Conclusions: Our data indicate that the ALOX15B gene may be associated with coronary 
artery disease. However, larger studies would be necessary to confirm the association of 
these polymorphisms with CAD. In contrast, our study excludes the presence of 
non-synonymous polymorphisms in ALOX15B altering enzyme activity in Europeans. 
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Introduction 
 
Atherosclerosis is a multifactorial disease characterized by lipid retention and chronic 
inflammation at susceptible sites in the arterial wall [14]. The progression leads to the 
formation of fatty streaks, early and late atheromas and can end in plaque rupture and 
thrombosis possibly causing myocardial infarction and stroke. Chronic inflammation is 
thought to be implicated at every stage of atherogenesis from the beginning by infiltration of 
leukocytes into the arterial intima until the clinical event of the thrombotic complications. In 
particular, activated macrophages, T-cells, mast cells, and recently also neutrophil have 
been detected in atherosclerotic lesions [5, 13, 14, 23]. 
The 12/15-lipoxygenases are involved in inflammation and have been shown to activate 
PPAR-γ through the production of fatty acid metabolites, to modulate the production of 
cytokines, to participate in the regulation of pro-atherosclerotic gene expression and to 
directly oxidize LDL [175]. From in vitro experiments there is compelling evidence that the 
12/15-lipoxygenase activity has pro- and anti-inflammatory effects, precluding a clear 
prediction of the role of these enzymes in atherosclerosis [171]. Even animal studies did not 
solve the question on the role of these enzymes in atherosclerosis with mouse and rabbit 
models showing contradictory outcomes [219, 261-263, 265, 272]. The discrepancies 
between the animal studies could be explained by the different expression pattern of the 
12/15-lipoxygenase iso-enzymes in each species with their different metabolite profile, and 
by the variable food composition used in the studies [171, 219]. 
In humans, there are 6 functional ALOX genes [273]. Two of them encode for arachidonic 
acid 12-lipoxygenating enzymes (ALOX12, ALOX12B) and two of them for 15-lipoxygenting 
proteins (ALOX15, ALOX15B). Previously, the role of the 15-lipoxygenase 1 (ALOX15) has 
been investigated in humans by genetic association studies in which the association of 
ALOX15 with coronary artery disease has been investigated [267, 269, 270] [71]. These 
studies supported a neutral to atheroprotective effect of ALOX15 in atherosclerosis.   
In our recent work, we found that the 15-lipoxygenase 2 (ALOX15B) is dominantly expressed 
in human macrophages suggesting that ALOX15B may be responsible for the majority of the 
12/15-lipoxygenase activity in human atherosclerosis [274]. Similarly, ALOX15B has been 
described as the most abundant 15-lipoxygenating enzyme species in carotid atherosclerotic 
lesions and to be associated with cerebrovascular symptoms [247]. 
To address the role of ALOX15B in human atherosclerosis, we screened the ALOX15B gene 
for polymorphisms and analyzed the association of the detected polymorphisms with 
coronary artery disease in a small case control study. We found that the polymorphisms at 
position c.1458-38G>C, c.1579+71C>T and c.1656G>A are in linkage disequilibrium and that 
they are associated with CAD. In addition we show that none of the three non-synonymous 
ALOX15B polymorphisms present in Europeans (p.Arg486His (c.1457G>A), p.Gln656Arg 
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(c.1967A>G) and p.Ile676Val (c.2026A>G)) alter the enzymatic properties of the enzyme, 
excluding a common non-synonymous polymorphism in ALOX15B which is functional. 
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Material and Methods 
 
Chemicals 
 
The chemicals used were obtained from the following sources: arachidonic acid 
(5Z,8Z,11Z,14Z-eicosatetraenoic acid) from Serva (Heidelberg, Germany), HPLC standards 
of 5(±)-HETE, 8(±)-HETE, 11(±)-HETE, 12(±)-HETE, and 15(±)-HETE from Cayman 
Chemicals (distributed by Spi Bio, Montigny le Bretonneux, France), sodium borohydride, 
ampicillin from Life Technologies, Inc. (Eggenstein, Germany), isopropyl-β-
thiogalactopyranoside (IPTG) from Carl Roth GmbH (Karlsruhe, Germany), HPLC solvents 
from Baker (Deventer, The Netherlands) and VWR International (Leuven, Netherlands). 
Arachidonic and linoleic acid were ordered from Sigma Aldrich (Hamburg, Germany). 
Restriction enzymes were purchased from Fermentas (St. Leon-Rot, Germany). The E. coli 
strain XL-1 blue was purchased from Stratagene (La Jolla, CA). 
 
Case control study 
 
340 men and 156 women participate voluntary in the study. Written informed consent was 
obtained from all participants and the Local Ethics Committee approved the study. The case 
sample consisted of 258 consecutive Caucasian patients with angiographically documented 
coronary artery disease with more than 50% stenosis in at least one coronary artery. The 
control group consisted of 238 persons with no history of CAD, stroke or peripheral vascular 
disease and was recruited from the general population. Angiographically negative individuals 
were also included in the control group. 80% of the cases were under cholesterol lowering 
medication and 87% received aspirin treatment [267, 275]. DNA has been extracted from 
EDTA-supplemented blood samples using the MagNA Pure LC DNA Isolation kit (Roche 
Diagnostics, Rotkreuz, Switzerland).  
 
Denaturing high-performance liquid chromatography (DHPLC) 
 
To detect polymorphisms in the ALOX15B gene denaturing high-performance liquid 
chromatography (DHPLC) has been carried out in a 96 well plate format. PCR was 
performed in 50 µl reaction volume containing 500 ng DNA. The primers, the amplicon size 
and corresponding annealing temperatures are listed in supplementary table 1. Primers were 
designed using OLIGO 6.0 software (Molecular Biology Insights, Inc., Cascade, USA) and 
ordered from Microsynth (Balgach, Switzerland). The PCR products were denatured for 
2 min at 95°C, cooled down to 60°C at a temperature ramp rate of 1°C/min, held at 60°C for 
1 min and cooled down to 4°C. DHPLC was carried out on a WAVE DNA fragment analysis 
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system (Transgenomic, Glasgow, UK) as previously described [268]. Samples with altered 
absorption pattern were analyzed by sequencing. 
 
Genotyping by high resolution melting (HRM) 
 
To genotype the different polymorphisms in our case control study high resolution melting 
analysis was used. The reaction was done on a Light Cycler 480 system (Roche 
Diagnostics) with the following parameters: pre-heating for 10 min at 95°C, followed by 45 
cycles of denaturation for 10 sec at 95°C, annealing for 10 sec at corresponding 
temperatures (supplementary table 2) and extension for 10 sec at 72°C, followed by the 
melting reaction starting with denaturing for 1 min at 95° followed by cooling down for 1 min 
at 40°C and ended by re-heating gradually from 65° to 95°C, and completed by cooling down 
for 10 sec at 40°C. The reaction volume of 10 µl included 15 ng DNA, 0.2 µM of each primer, 
forward and reverse, appropriate magnesium chloride concentration (supplementary table 2) 
and 2 x High Resolution Melting Master Mix (LightCycler® 480 High Resolution Melting 
Master Kit, Roche Diagnostics). The primers (Microsynth) were designed with the OLIGO 6.0 
software and the sequences are listed in supplementary table 2.  
 
Genotyping by fluorescence resonance energy transfer (FRET) 
 
To genotype the c.-40A>G polymorphism fluorescence resonance energy transfer method 
(FRET) was used. The primers and probes were ordered from TIB MOLBIOL (Berlin, 
Germany) and the sequences are listed in supplementary table 2. The reaction volume of 
10 µl included 20 ng DNA, 0.5 µM of each primer, forward and reverse, 0,2 µl probes and 5 x 
Genotyping Master Mix (LightCycler® 480 Genotyping Master Kit, Roche Diagnostics). The 
reaction was done on a Light Cycler 480 system (Roche Diagnostics) utilizing the following 
parameters: pre-heating for 10 min at 95°C, followed by 50 cycles of denaturation for 10 sec 
at 95°C, annealing for 10 sec at 58°C and extension for 10 sec at 72°C, completed by the 
melting reaction in the temperature interval from 40° to 85°C. 
 
Genotyping by fragment length analysis 
 
To determine the genotype of the ALOX15B deletion at position c.-431delAAAT in our case 
control study, fragment length analysis was performed using a fluorescein (FAM) labelled 
primer (Microsynth) (supplementary table 2). After amplification of the region by PCR 
reaction, 1 µl PCR product and 1 µl of internal standard (GeneScan 500 ROX, Applied 
Biosystems, Zug, Switzerland) were added to 12 µl formamide (Sigma-Aldrich, Buchs, 
Switzerland), denatured for 4 min at 95°C and analyzed on a 3500 Genetic Analyzer (Applied 
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Biosystems). Processing of the obtained data was done with the GeneMapper V.4.1 program 
(Applied Biosystems). 
 
Sequencing 
 
Four of the polymorphisms were analysed by sequencing with a 3130xl Genetic Analyser 
(Applied Biosystems). After amplification of the fragment by PCR, the sequencing reaction 
was performed with 3 µl purified PCR product in 10 µl reaction volume with the BigDye 
Terminator v 1.1 Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer’s 
instructions. The primers were ordered from Microsynth and are listed in supplementary 
table 2. Analysis of the data was done using the SeqMan Pro program (DNASTAR, Inc., 
Madison, USA). 
 
Bacterial expression and purification of human ALOX15B as a His-tagged fusion protein 
 
E.coli XL1 blue bacteria were transformed with the recombinant pQe-9 plasmid containing 
the coding sequence of the human ALOX15B, and 5-10 bacterial clones were grown 
overnight at 37°C in 20 ml LB-media containing 100 µg/ml ampicillin. For the main culture 1.5 
l of LB media containing 100 µg/ml ampicillin were inoculated with 10 ml bacterial pre-culture 
and shaken for approximately 16 hrs at 37°C until an OD of 3-5 was reached. In total 18 l LB 
media was used for each enzyme preparation. Expression of the recombinant protein was 
induced by addition of 1 mM IPTG (final concentration) and the culture was kept at 28 °C for 
4 hrs. Bacteria were spun down, washed and resuspended in 20 ml PBS. Bacterial cells 
were lysed by sonification. The cellular debris was removed by centrifugation and lysis 
supernatant containing the soluble protein fraction was loaded on a 2 ml Ni-NTA agarose 
affinity chromatography column (Macherey-Nagel GmbH, Dueren, Germany). The column 
was washed four times with 2 ml washing buffer containing either 10 or 25 mM imidazole to 
remove loosely bound proteins. His-tagged human ALOX15B protein was eluted from the 
column by adding 6 times 0.6 ml elution buffer containing 200 mM imidazole. Five elution 
fractions were collected, desalted and further purified by an anione exchange 
chromatography using a ResQ column (6 ml) (GE Healthcare, Chalfont St Giles, GB). The 
purified enzyme fractions were stored for further use at -80°C in a storage buffer (20 mM 
Tris/Cl, 200 mM NaCl) containing 10 % (v/v) glycerol pH=8.0.  
 
Site-directed mutagenesis 
 
Site-directed mutagenesis was performed using the QuikChangeTM Site-Directed 
Mutagenesis Kit (Stratagene, Amsterdam, The Netherlands). After mutagenesis the mutated 
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expression plasmid was transformed into competent E.coli XL-1 blue cells. The plasmid DNA 
was isolated from one of the resulting bacterial clones and mutation was verified by DNA 
sequencing.  
 
Product specificity assays 
 
LOX activity of purified enzyme preparations was assayed by reverse phase 
high-performance liquid chromatography (RP-HPLC) quantification of arachidonic acid (AA) 
oxygenation products. 10 µl of the enzyme preparation was incubated for 15 min at 37°C with 
150 µM arachidonic acid. The formed hydroperoxy fatty acids were reduced with sodium 
borohydride to the corresponding hydroxy derivatives, the mixture was acidified to pH 3 by 
adding acetic acid, and 0.5 ml of ice-cold methanol was added. The protein precipitate was 
spun down, and aliquots of the clear supernatant were injected to RP-HPLC. 
 
Reverse phase HPLC analytics 
 
RP-HPLC of the ALOX products was performed on a Shimadzu LC20 system (Shimadzu 
Deutschland GmbH, Duisburg, Germany) equipped with an autoinjector facility by recording 
the absorbance at 235 nm. RP-HPLC was carried out on a Nucleodur C18 Gravity column 
(Macherey-Nagel; 250 x 4 mm, 5 µm particle size) coupled with a guard column (8 x 4 mm, 5 
µm particle size). A solvent system of methanol/water/acetic acid (85/15/0.05, by volume) 
was used at a flow rate of 1 ml/min. 
  
Kinetic measurements 
To determine kinetic parameters (turnover number kcat and Michaelis constant Km) the 
reaction kinetics were analyzed with a Shimadzu UV-2102 PC Spectrophotometer at 235 nm 
(formation of conjugated dienes). For this purpose 8 µg enzyme was incubated with 2.5 to 50 
µM linoleic acid (LA) in 1 ml total reaction volume (PBS, pH=7.5) and the reaction was 
followed at 30°C for up to 240 sec.   
 
Melting curve analysis 
 
A 2.5 fold molar excess of the fluorescent dye SyproOrange® (Carlsbad, California, USA) 
was incubated with 3 µM purified LOX enzyme in 20 mM Tris/Cl 150 mM NaCl pH= 8.0 (total 
volume = 20 µl). Heat denaturation of the enzyme was performed with a Rotor-Gene 
RG-3000 real-time PCR machine (Corbett Research, Cambridge, United Kingdom) heating 
up the samples from 30 to 95 °C (0.5 °C/sec). In the absence of proteins the intensity of the 
fluorescent dye is quenched in aqueous solutions. The temperature increase causes a 
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thermal unfolding of the protein and then the hydrophobic core regions are exposed to the 
surface. SyproOrange® binds to the hydrophobic regions and becomes unquenched leading 
to an increase in fluorescent intensity. The resulting fluorescent was detected using a 
FAM/SYBR green filter. The software Rotor-Gene 4.6 was used for calculation of the 
negative first derivative of the raw data. The inflection point of the melting transition is the 
melting point Tm. 
 
Statistics 
 
Haplotype analysis was calculated with HaploView (Daly Lab at the Broad Institute, 
Cambridge, MA 02141, USA) [276] which uses a standard expectation maximization 
algorithm together with a partition–ligation approach. The pairwise linkage disequilibrium 
(LD) between the SNP was also calculated with HaploView using Lewontin’s standardized 
disequilibrium coefficient D’ [277] and the standardized coefficient r2 which is the square of 
the correlation coefficient between two indicator variables. Statistical analysis has been done 
using SPSS 20 (IBM SPSS Statistics, Version 20, Zurich, Switzerland). Data of the 
association study were analyzed by binary logistic regression in an additive genetic model 
adjusted for sex and age. To assess the differences of the characteristics between the case 
and control groups in our study, Mann-Whitney U tests have been carried out. The 
differences have been provided as the asymptotic significance 2-tailed p-value.   
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Results 
 
Identification of genetic variants in the ALOX15B gene 
 
We screened approximately 1500 bp of the promoter region, all the exons including 
intron/exon boundaries, and the 3’UTR of the ALOX15B gene for polymorphisms in 88 DNA’s 
from volunteers and CAD patients of our case control study. We found eighteen variations 
listed in table 2. Three variations are located in the region upstream of the gene, one in the 
5’UTR, nine in the coding region, two in introns and three in the 3’UTR region. The three 
variations located in the exons at position c.1457G>A, c.1967A>G and c.2026A>G were 
non-synonymous polymorphisms leading to an amino acids exchange from arginine to 
histidine at position p.486, glutamine to arginine at position p.656 and isoleucine to valine at 
position p.676.  
 
Association of polymorphisms predicting CAD status for cases 
 
To investigate the association of the detected polymorphisms with atherosclerosis, we 
analyzed the genotype of the different polymorphisms in our case control study including 258 
cases with angiographically documented CAD and 238 healthy volunteers. Characteristics of 
cases and controls are shown in table 1. All variations occur with higher frequencies than 1% 
and qualify as single nucleotide polymorphisms (SNP) except for the deletion polymorphism 
at position c.-431delAAAT. The genotype frequencies of all polymorphisms were in 
Hardy-Weinberg equilibrium. Using linear regression analysis with an additive model, three 
polymorphisms c.1458-38G>C, c.1579+71C>T and c.1656G>A showed an association with 
coronary artery disease (CAD) with an odds ratio (OR) of 0.51 (0.27-0.94; p-value of 0.03). 
Additionally, two SNP’s at position c.705C>T showed a trend to be associated with CAD with 
an OR of 0.80 (0.62-1.03; p-value of 0.09) and c.1967A>G with an OR of 0.81 (0.62-1.04; 
p-value of 0.10), respectively (table 2).  
 
Haplotype frequencies and linkage disequilibrium analysis 
 
The haplotype frequencies are outlined in table 3. Linkage analysis revealed that two sets of 
three polymorphisms are inherited together. The polymorphisms c.1458-38G>C, 
c.1579+71C>T and c.1656G>A as well as the three polymorphisms c.1767C>T, c.2026A>G 
and c.*122C>A showed complete linkage disequilibrium (D’=1, r2=1) (supplementary table 3). 
Analyzing the 18 polymorphisms, we detected 11 haplotypes with a frequency higher than 
1% in this European sample (table 3). The most frequent haplotype (nr.1) contains three 
substitution (c.-537A>G; c.-40A>G; c.345C>G; 27.4%) followed by the haplotype nr.2 with 
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four substitution (c.705C>T; 1440C>T; 1650C>A; 1967A>G; 24.2%) and the haplotype nr.3 
with the deletion at position c.-431delAAAT (20.1%). No association was observed for any of 
the haplotypes with CAD (data not shown).  
 
Functional investigation of the non-synonymous polymorphisms 
 
Since the non-synonymous polymorphism c.1967A>G showed a trend for an association with 
CAD, we decided to investigate the influence of all the non-synonymous variations in 
ALOX15B on the enzyme activity in silico and in vitro. In silico prediction by the PolyPhen-2 
software suggested that the polymorphism at position c.2026A>G is possibly damaging while 
the polymorphisms at positions c.1457G>A and c.1967A>G are benign. To test whether 
these polymorphisms would affect the ALOX15B enzyme activity in vitro, we expressed the 
ALOX15B enzyme in E.coli. Wild type and mutant proteins (p.Arg486His, p.Gln656Arg and 
p.Ile676Val, figure 1) were purified to ~ 90% homogeneity (supplementary figure 1), and their 
activity was estimated by quantification of the arachidonic acid (AA) and linoleic (LA) 
oxygenation products 15-HETE and 13-HODE, respectively (supplementary figure 2). We 
found that all analyzed variants have a similar catalytic activity and the same product 
specificity compared to the wild-type enzyme (figure 2, table 4). In addition, the turnover (kcat) 
and the Michaelis constant (Km) values of the variants for linoleic acid are similar to the 
wild-type enzyme. The thermodynamic shift analysis showed that the denaturation curves 
and resulting melting points of the different mutant variants are also similar to that of the 
wild-type enzyme, with the exception of p.Ile676Val which has a ~ 2.4°C decreased melting 
point suggesting that this polymorphism could destabilize the tertiary structure of the enzyme 
(table 5). 
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Discussion 
 
In this study we identified eighteen polymorphisms in the ALOX15B gene and analyzed the 
association of the detected variations with coronary artery disease (CAD) in a case control 
study involving 496 Caucasians. We found that the polymorphisms at position c.1656G>A, 
c.1579+71C>T and c.1458-38G>C are in perfect linkage disequilibrium in this European 
sample and that they are associated with CAD (OR: 0.51 (0.27-0.94), p-value: 0.03).  
These SNP’s are either located in the non-coding region (c.1579+71C>T and c.1458-38G>C) 
or result in a synonymous polymorphism (c.1656G>A) not leading to a codon substitution, 
which makes it difficult to predict a functional effect on the ALOX15B enzymatic activity. 
Although intronic and synonymous SNP’s have often been assumed to not exhibit an effect 
on gene function, there is emerging evidence that they could indeed have an effect. For 
example there is indication that intronic variants can lead to exonization of intronic 
sequences or exon skipping [278-280], and that even synonymous variants may affect 
translational kinetics leading to a different protein conformation and consequently altered 
protein function [281, 282]. Although our results show an association with CAD for these 
SNP’s, larger studies would be necessary to confirm the association of these polymorphisms 
with CAD, before the potential mechanism of the synonymous polymorphism c.1656G>A 
should be investigated.  
We also observed a trend for an association of the non-synonymous polymorphism 
c.1967A>G (p.Gln656Arg) with CAD, however, in vitro data of the enzyme kinetics did not 
reveal a functional effect of the polymorphism. Measurement of enzyme activity and 
specificity revealed no difference in the catalytic activity and product specificity between the 
mutant (p.Gln656Arg) and the wild-type form. In addition, investigation of the enzyme 
properties showed that the Michaelis-Menten parameters, the turnover number kcat and the 
Michaelis constant Km of p.Gln656Arg are similar to the wild-type enzyme for linoleic acid. 
Thus, the exchange of the amino acid at the indicated position did not have an impact on 
enzyme activity in vitro. Similarly, none of the other non-synonymous SNP’s altered the 
enzymatic activity of ALOX15B. 
15-lipoxygenases metabolize arachidonic acid to produce the metabolite 15-HETE which can 
further be converted into lipoxins [178]. 15-HETE has been shown to exhibit 
anti-inflammatory activity by suppression of superoxide production and degranulation of 
leukotriene B4 (LTB4) stimulated polymorphonuclear neutrophils (PMN) [258], by inhibition of 
LTB4 induced chemotaxis of PMN [283] and by inhibition of PMN migration through cytokine 
activated endothelium in vitro [209]. Further, the arachidonic acid metabolite 15-HETE can 
be metabolized by ALOX5 into lipoxin A4 and B4, lipid mediators which have potent 
anti-inflammatory and pro-resolving properties. For example, these lipoxins have been 
shown to arrest leukotriene B4 induced chemotaxis and infiltration of neutrophils as well as to 
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stimulate the uptake of apoptotic cells by macrophages [71]. These properties argue for an 
anti-inflammatory effect of 15-lipoxygenases which could antagonize atherogenesis. 
However, it has also been shown that 15-lipoxygenases exhibits pro-atherogenic properties 
by contributing to LDL oxidation and by supporting signal transduction of angiotensin II [171]. 
Additionally, 15-HETE increased the expression of the scavenger receptor B (CD36) which is 
involved in the uptake of LDL into macrophages, another pro-atherogenic process [250].  
It is not clear whether the 15-lipoxygenase activity is pro- or anti-atherogenic in humans. 
While there is indication for a neutral or atheroprotective effect of ALOX15 in human 
atherosclerosis [71], our study cannot delineate the role of ALOX15B in human 
atherosclerosis due to the lack of a functional SNP in ALOX15B. The line of evidence 
published so far favours a pro-atherosclerotic role of ALOX15B. Silencing of ALOX15B in 
human macrophages decreased cellular lipid accumulation and the secretion of 
pro-inflammatory cytokines [271], while over-expression of ALOX15B in these cells leads to 
increased secretion of the chemokine CXCL10, which promotes atherogenesis and induces 
T cell migration [284, 285]. Additionally, experiments in mice showed that knockdown of 
mouse ALOX15B, which oxygenates arachidonic acid to 8-HETE, reduced atherosclerosis, 
subendothelial lipid accumulation, plaque T cell content and the plasma level of the 
pro-inflammatory cytokine IL-2 [271]. Nevertheless, since the mouse ALOX15B has a 
different positional selectivity than the human homologue ALOX15B, it is not clear whether 
these findings are transferable to humans.   
In summary, we found an association of three rare and completely linked polymorphisms with 
CAD and we surmise that larger studies with the necessary power to investigate the 
association of these polymorphisms in ALOX15B with CAD or myocardial infarction would 
dissect the role of ALOX15B in human atherosclerosis. 
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Figure legends: 
 
Figure 1: Location of the observed non-synonymous variations in human ALOX15B detected 
in the European sample using Protein Model Data Base PM0078035.  
 
Figure 2: Relative activity of the different ALOX15B variants estimated by quantification of 
the oxygenation products after incubation of the different enzymes with either arachidonic 
acid (black) or linoleic acid (dottet). 
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Table 1: Characteristics of cases and controls 
 controls (n=238) cases (n=258) p-value 
age, years 59 (53 - 66) 64 (57 - 71) < 0.0001 
male, % 58.0 78.4 < 0.0001 
history of hypertension, % 29.1 46.3 < 0.0001 
history of diabetes, % 3.6 20.8 < 0.0001 
history of high cholesterol, % 19.8 51.0 < 0.0001 
smoking, % 47.3 73.4 < 0.0001 
body mass index, kg/m2 25.7 (23.0 – 28.4) 26.8 (24.4 – 30.0) < 0.0001 
creatinine, umol/L 90 (83 – 99) 89 (80 – 99) 0.45 
hsCRP, mg/L 1.3 (0.6 – 2.7) 1.8 (0.9 – 4.0) <0.0001 
cholesterol, mmol/L 5.9 (5.1 – 6.5) 5.1 (4.4 – 5.9) < 0.0001 
HDL, mmol/L 1.6 (1.3 – 2.0) 1.3 (1.1 – 1.5) < 0.0001 
LDL, mmol/L 3.5 (2.8 – 4.0) 3.2 (2.5 – 3.9) 0.001 
triglycerides, mmol/L 1.4 (0.9 – 2.0) 1.3 (1.0 – 1.8) 0.77 
Results are presented as median (interquartile ranges) or percentage 
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Table 2: Association of polymorphisms with CAD   
NM_001141.2 genotype controls, % genotype cases, % OR 95% CI p-value 
c.-1106A>G 
rs79235239 
97.5/2.5/0 96.5/3.5/0 1.51 0.50-4.53 0.47 
c.- 537A>G 
rs8075588 
34/45.8/20.2 32.9/49.6/17.4 0.94 0.73-1.23 0.67 
c.-431delAAAT 
rs59119570 
62.2/31.5/6.3 55.4/38.4/6.2 1.21 0.89-1.63 0.23 
c.-40A>G 
rs73972649 
50.4/40.3/9.2 49.6/41.5/8.9 1.06 0.80-1.40 0.70 
c.345C>G 
rs76589243 
44.1/41.6/14.3 42.6/43.8/13.6 1.03 0.79-1.34 0.83 
c.705C>T 
rs6503070 
30.3/48.7/21 37.2/45/17.8 0.80 0.62-1.03 0.09 
c.1440C>T 
rs11541083 
46.2/41.2/12.6 48.4/38.8/12.8 0.95 0.73-1.24 0.71 
c.1457G>A p. 
Arg486His 
rs9895916 
94.1/5.9/0 95.3/4.7/0 0.96 0.41-2.23 0.92 
c.1458-38G>C 
rs11870212 
c.1579+71C>T 
rs60050159 
c.1656G>A 
rs61312861 
89.5/9.7/0.8 92.6/7.4/0 0.51 0.27-0.94 0.03 
c.1650 C>A 
rs9898751 
34.9/48.3/16.8 40.3/43.8/15.9 0.84 0.64-1.09 0.18 
c.1767C>T 
rs9904554 
c.2026A>G  
p.Ile676Val 
rs7225107 
c.*122C>A 
rs1804772 
96.2/3.8/0 95.7/4.3/0 1.22 0.47-3.13 0.68 
c.1967A>G 
p.Gln656Arg 
rs4792147 
23.5/48.7/27.7 28.7/47.3/24 0.81 0.62-1.04 0.10 
c.*226A>T 
rs117777987 
93.7/6.3/0 93.8/6.2/0 0.98 0.46-2.11 0.96 
c.*348A>G 
rs1132934 
81.5/17.2/1.3 82.6/15.1/2.3 0.95 0.63-1.45 0.82 
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Table 3: Haplotypes and haplotype frequencies 
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Table 4: Relative enzyme activity of the different ALOX15B variants   
hALOX15B variant 
share 15-HETE 
(%) 
rel. activity % 
(AA) 
share of 13-
HpODE % 
rel. activity % 
(LA) 
wild-type > 99 100.0 ± 2.4 95.0 ± 1.0 100.0 ± 5.7 
p.Arg486His 
(rs9895916) 
> 99 100.4 ± 1.5 95.0 ± 1.0 95.7 ± 5.9 
p.Gln656Arg 
(rs4792147) 
> 99 94.0 ± 6.9 95.0 ± 1.0 84.4 ± 0.9 
p.Ile676Val 
(rs7225107) 
> 99 104.2 ± 0.3 95.0 ± 1.0 94.1 ± 3.1 
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Table 5: Michaelis-Menten kinetics and thermodynamic shift analysis 
hALOX15B variant 
turnover number kcat (s-
1) 
Km (µM) 
melting temperature Tm 
(°C) 
wild-type 0.18 ± 0.01 1.2 ± 1.2 57,4 ± 0,2 
p.Arg486His 
(rs9895916) 
0.27 ± 0.02 2.8 ± 0.8 56,6 ± 0,3 
p.Gln656Arg 
(rs4792147) 
0.25 ± 0.02 3.7 ± 0.02 56,9 ± 0,2 
p.Ile676Val 
(rs7225107) 
0.18 ± 0.01 1.04 ± 0.6 55,0 ± 0,3 
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Figure 1: 
 
  
 
 
 
Figure 2:  
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Supplementary tables and figures: 
 
PCR 
Nr. 
primer sequences (5’-3’) 
amplicon size 
(bp) 
PCR annealing 
temp. °C 
DHPLC oven 
temp. °C 
1 CAGCTTGTGCCTCTTCTCTTCT 
AGTGAGGTGAAGTTGTGCCATT 
592 56 60/64 
2 CCACCTCTGCTTCTCACTCCTT 
CGCCCAGCCTACATTCATTATT 
472 56 56/60/62 
3 TGGGCCTTTATCAATAGCAGTG 
TGGGAACAGGAGGGACTAAGAA 
607 56 56/58/61 
4 GGTCCCAACTCTAGGCTCTCTG 
TGAGGGGAGGTTAAGTATGCGT 
532 60 61/63/65/67 
5 TGTGAGTGCGTGGGAGTGGATG 
GGAGTAGGTTGGGGTGGGGAGA 
587 60 64/68/70 
6 GTAGAGGGTGGCAATCGTGGAG 
TGATAGGAGAGGTGGAGGCAGG 
281 60 55/58/62/64/66 
7 TTGGGTAGAATGGAAGGGCAGC 
TGTCAGCCAGCCTTATGCCTCT 
510 60 61/64/67 
8 CTACCAATCCCACAGAGCAACA 
ATCCCCTCCGTCCATATTCTCT 
425 60 59/61/64 
9 GATTTGCTGCTGGGTGAAGAGG 
GATTCAGGGCTGGGAGAGGAGT 
519 60 62/64/66 
10 CTTCTACAACTGCACCCCCTTC 
GGATAGGGCCATGTGAGGAAAG 
599 60 62/68/70 
11 CTCATTCTTGTTGCCTCTTTCC 
CATCCCATCATCACGGTAGTAG 
501 60 62/64/66/68 
12 TATTCTCTCCTGTGTCTGCCTG 
CTTGGACAGACTCATCACTTGG 
341 56 58/62/66 
13 AGGAGGGCCAGACATTCATGAT 
CCCTGTACCTGAGCTCTCCTGG 
220 56 60/64/66 
14 CCCAAGTGATGAGTCTGTCCAA 
CAACCAGAGAGCAAGGATGACA 
604 60 62/65 
15 GATATTCACCTGCTCCGCCAAG 
GCCAGCAGGGTAAACATCACAC 
368 60 60/62/64/67 
16 GGCTACTTCAGGTCCCACACTT 
GTGGTGGGGGTGAGTTACAGAG 
466 60 62/65 
17 ATCCCTTTGACCACATCGCTCT 
GCTGGCCTTGAACTTCTGACCT 
486 60 60/63/66 
18 TCACCCAACTCAAGGACAGCCA 
CTCAAGCAGTCCTCCCACCTCA 
254 60 56/60/64 
19 GACGACATAGCGAGACTCCACC 
GTGTTCTCATTCTGCCTGGCTC 
626 60 56/61/65 
 
Supplementary table 1: Primers and conditions for denaturing high-performance liquid 
chromatography (DHPLC) experiments 
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number primer sequences (5’-3’) amplicon 
size 
PCR annealing 
temp. °C 
method MgCl2-conc. 
mM 
rs79235239 
CTGCTTCTCACTCCTTCACATT 
GAGGTGAAGTTGTGCCATTG 
167 55 HRM 3 
rs184617271 
GTTCAAGCTATTCTCCTGCCTC 
ACCTAGTGCTTGCTCTCATGGA 
174 58 HRM 2 
rs8075588 
CTCGCCTGTTGTCTCAGCTA 
GGCCTGCGTTCATTATTTTT 
174 55 HRM 3 
rs59119570 
FAM-CAGGAGGAGGAGGTTCCAGT 
ATATCACCCCATTTCCCACA 
150 57 FA  - 
rs73972649 
primers:  CGTGTTCCAGCCTCTCCG 
               TGGACACCCTGACCCTGAAC 
probe:    CTCTGCAGCCCTGTGCGCC--FL 
anchor:  LC640-AGAGAGCTGGACTTA 
              GGCTGGCAGCATGGC--PH 
204 58 FRET - 
rs76589243 
ATGCCTGGTTCTGCCGCTGGTT 
CTCTCCATTTCACCTGCCCTTCTC 
204 63 HRM 2 
rs6503070 
GCAGAGCACGCATTTGAGCACT 
GCATCAGTGACGGGGAAGTTCT 
125 60 HRM 3 
rs11541083, 
rs9895916 
rs11870212, 
rs60050159 
rs9898751, 
rs61312861 
ACAGGCATCGGCATTGAAGG 
CGAGAGGGCAGAATGAGGCT 
 
827 
 
60 SEQ - 
rs9904554 
CTCTCGGCCTTCAGTTTGAC 
ACTTGGTCTCCAGGCTCCTT 
187 60 HRM 2 
rs4792147 
GAGCATCGCCACCTTCCAGA 
TCGATGAGGGGAGGGTCTAGGT 
108 60 HRM 3 
rs7225107 
TACACCTACCTAGACCCTCC 
TAGAGCGATGTGGTCAAAG 
99 55 HRM 3 
rs1804772 
GCACCCAGAGAAAAGGACT 
TTGTGTGTGTGTATGGTGGT 
102 55 HRM 3 
rs117777987 
GTGCCTCTCCTGGGACAA 
GGCACTTTGAGGCTTGGAG 
163  55 HRM 5 
rs1132934 
GAGGGTTTTGCTAGTTGGT 
CCATAAGGTCCAATCAGTG 
102 55 HRM 3 
 
Supplementary table 2: Primers and conditions for genotyping experiments using high resolution 
melting (HRM), fluorescence resonance energy transfer (FRET), fragment analysis (FA) or 
sequencing (SEQ) method 
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Supplementary table 3: D’ and r2 data of the pairwise linkage disequilibrium (LD) between the SNPs
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Supplementary figure 1: SDS page gel of the different human ALOX15B protein variants after 
expression in E.coli and purification. 1: wt, 2: p.Arg486His, 3: Ile676Val, 4: Gln656Arg 
 
 
 
 
Supplementary figure 2:  Example (wild-type and the mutation p.Arg486His) of reverse phase 
high-performance liquid chromatography (RP-HPLC) of the ALOX15B products  
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3. DISCUSSION 
 
Atherosclerosis is a multifactorial disease with the two main features: lipid retention 
and inflammation at susceptible sites in the arterial wall [5]. The 12/15-LOX and their 
products have been shown to be implicated in inflammation and the correspondent diseases 
whereas both pro- and anti-inflammatory effects have been described [173]. In 
atherosclerosis, 12/15-LOX play a dual role with an anti-inflammatory effect through 
generation of lipid mediators involved in the resolution of inflammation, and a 
pro-atherogenic effect through lipid oxidation and contribution to signalling pathways. The 
role of the 12/15-LOX gene has been investigated in mouse and rabbit models of 
atherosclerosis and resulted in conflicting data suggesting pro- and anti-atherogenic activity 
[219, 261-263, 265, 272, 286]. The discrepancies between the animal studies could be 
explained by the different expression pattern of the 12/15-LOX iso-enzymes in each species 
with subsequently different metabolite production, and by the variable food composition used 
in the studies [171, 219]. In humans, there are two 12-LOXs and two 15-LOXs; these show 
different expression patterns, substrate specificities and stereo-selective metabolism [171], 
but in cells involved in atherogenesis only  ALOX15 and ALOX15B are expressed [247]. In 
addition to, and to resolve the contrasting results between the different animal studies, 
ALOX15 has been investigated in human atherosclerosis. In genetic case control studies, 
two polymorphisms in the ALOX15 gene showed to be associated with coronary artery 
disease (CAD) indicating a neutral to an atheroprotective role of this enzyme  [267, 269, 
270].  
ALOX15B, discovered in 1997, has recently been shown to be expressed in human 
atherosclerotic plaques and to be associated with cerebrovascular symptoms [247]. The 
studies of this enzyme in the context of experimental atherosclerosis have indicated a 
pro-atherogenic role in vitro as well as in LDLR-/- mouse studies. However, the role of 
ALOX15B in human atherosclerosis is still unclear. To address this, I aimed in this thesis to 
investigate the regulation of the expression of different 12/15-LOXs in human macrophages, 
which are key player cells in the development of atherosclerotic plaques. Additionally, I 
screened the ALOX15B gene for polymorphisms and analysed the association of selected 
polymorphisms in our case control study with angiographically documented CAD. 
In the first part of this study, I investigated the expression of ALOX12, ALOX15 and 
ALOX15B in human macrophages and tested the effect of different stimuli on their 
expression. I found that ALOX15B is the main expressed 12/15-LOX in human 
macrophages, and that the cytokine IL-4, the TLR 4 agonist, LPS and hypoxia increase its 
expression at the mRNA and protein levels. The cytokine IL-13 enhanced the mRNA 
expression of ALOX15B but this effect could not be confirmed at the protein level. The 
expression of ALOX15 mRNA and protein was increased after IL-4 and IL-13 stimulation 
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similar to the previously described increase in human monocytes [287]. However, only 
stimulation with IL-4 seems to induce ALOX15 expression to levels higher than the basal 
expression of ALOX15B. None of the stimuli had an impact on ALOX12 expression. 
Twenty years ago, ALOX15 was detected in early lesions [245] and was shown to 
co-localize with epitopes of oxLDL [244] in macrophage-rich regions as well as in human 
fatty streaks and more advanced atherosclerotic lesions [288]. It was thought that ALOX15 
might be mainly responsible for the 12/15-LOX activity in human atherosclerosis. However, 
Rydberg et al. found that ALOX15B is expressed in carotid atherosclerotic plaques [153], and 
Gertow et al. reported recently that ALOX15B is the most abundant 12/15-LOX expressed in 
carotid lesions and furthermore, that it is associated with cerebrovascular symptoms [247]. 
Corroborating to this, my findings show that ALOX15B is the mainly expressed 12/15-LOX in 
human macrophages and that only IL-4 seems to induce ALOX15 expression to levels higher 
than the basal expression of ALOX15B, suggesting that ALOX15B might play a more 
important role in human atherosclerosis than ALOX15. 
Macrophages play a crucial role in the initiation, maintenance and resolution of 
inflammation [289], a process which mediates all stages of atherosclerosis from initiation to 
ultimately thrombotic complication [5]. They can be polarized into different types of cells, the 
classical activated M1 and the alternatively activated M2 macrophages. The Th2 cytokines 
IL-4 and IL-13 induce the M2 macrophages which are considered to be involved in 
anti-parasite actions, tissue remodelling and tumour progression and are thought to possess 
anti-inflammatory properties. The bacterial fragments LPS activate the differentiation into a 
M1 phenotype which is characterized by the production of pro-inflammatory mediators such 
as IL-1, IL-6 and TNF as well as oxygen intermediates [290, 291]. Both types of 
macrophages have been detected in different preferential regions during the development of 
atherosclerotic plaques [139]. Although their role in the process of atherogenesis has not 
been fully elucidated, the recent finding that M1 macrophages are preferentially located at 
the plaque shoulder - which is a key prone rupture area - suggests that macrophage 
polarization might play a critical role in the plaque stability [292]. Thus, it is thought that 
macrophage heterogeneity may play an important role in the progression and outcome of 
atherosclerosis and that an imbalance in the ratio of M1/M2 macrophages might result in an 
impaired resolution of the inflammatory status [134]. My results revealed that in 
LPS-stimulated M1 macrophages only ALOX15B is expressed; in contrast in IL-4 stimulated 
M2 macrophages ALOX15 and ALOX15B are both responsible for the 12/15-LOX activity. As 
M1 macrophages are thought to rather exhibit pro-inflammatory and pro-atherogenic activity, 
the unique expression of ALOX15B in this macrophages type would presume a pro-
atherogenic role. However, the fact that the anti-inflammatory cytokine IL-4 induced 
ALOX15B expression as well questions this interpretation and indicates that ALOX15B might 
have a dual role in atherosclerosis.  
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The situation in atherosclerotic plaques is quite complex and it is thought that 
heterogeneity of rather than the simple M1 and M2 paradigm might be the reality. Thus I will 
now discuss the various stimuli which had an excitatory effect on ALOX15 and ALOX15B 
expression in my study and their role in atherosclerosis.  
Several studies have investigated the role of IL-4 and IL-13 in atherosclerosis. There 
is evidence that they exhibit important roles in the regulation of inflammatory responses and 
that they share many biological activities such as the inhibition of the inflammatory cytokine 
production, the counteraction of the IFN-γ actions [290] and the reduction of inflammation in 
animal models of arthritis [293, 294]. IL-4 and IL-13 share a common signalling pathway, the 
JAK/STAT pathway, and they both use a complex receptor system including the interleukin 4 
receptor (IL-4R) for the transduction of the signal. Recently, the study of IL-4/IL-13 signalling 
in human monocytes/macrophages revealed that there are some differences in the signalling 
pathways as IL-4 use only the IL-4Ra/Jak1/Stat3/Stat6 pathway whereas IL-13 utilize either 
IL-4Ra/Jak2/Stat3 or IL-13Ra1/Tyk2/Stat1/Stat6 pathway to induce the expression of 
anti-inflammatory genes [295]. In human monocytes, IL-4/IL-13 down-regulated the 
expression of pro-inflammatory mediators such as IL-1, IL-6, IL-8, IL-18, MCP-1 and TNF-α 
as well as the expression of the enzymes involved in pro-inflammatory eicosanoids 
biosynthesis such as the cyclooxygenase and the 5-LOX. Additionally, IL-4/IL-13 increased 
the expression of molecules with anti-inflammatory properties including fibronectin, 
monoamine-oxidase A and coagulation factor XIII [287]. In contrast, pre-treatment with IL-4 
and IL-13 enhanced the ability of human monocytes to oxidize LDL in vitro [296] which was 
accompanied by an increase in ALOX15 expression and presumably contributing to the 
oxidation of LDL as it has been previously described [297]. In addition, IL-4 and IL-13 have 
been described to induce, through activation of PPAR-γ, CD36 expression, a receptor 
involved in the uptake of modified lipoprotein [250, 298]. The in vitro studies indicate 
evidence for a possible two-faced function of IL-4 and IL-13 in atherogenesis: by an 
anti-inflammatory effect and by LDL oxidation. This dual role has also been described for 
ALOX15 [171] as it produces anti-inflammatory lipid mediators and oxygenates lipoproteins 
in vitro [167], which are key players in atherogenesis. A possible common involvement of 
IL-4 and 12/15-LOX in atherosclerosis has been shown by Huang et al. who showed in vitro 
that the coordinate production of 12/15-LOX and PPAR-γ is responsible for CD36 gene 
expression in macrophages and suggested that 12/15-LOX plays a role in the generation of 
endogenous ligands for PPAR-γ [250]. The individual role of IL-4 and IL-13 in atherosclerosis 
has already been studied in vivo. For example, IL-4 deficient ApoE mice developed fewer 
atherosclerotic plaques indicating a pro-atherogenic role for endogenous IL-4 [299]. 
However, another report did not find an effect of IL-4 administration to ApoE-/- mice on the 
development of atherosclerotic plaques [92] suggesting that exogenous and endogenous 
IL-4 might have diverging effects. Cardilo-Reis et al. showed that administration of IL-13 to 
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LDLR-/- mice modulated the morphology of established lesions toward an less vulnerable 
phenotype by promoting collagen formation, reducing monocyte recruitment and inducing a 
switch toward M2 type macrophages [300]. All of these studies revealed a role of these two 
cytokines in atherosclerosis; however, whether there is a connection between IL-4 or IL-13 
and the 12/15-LOX remains to be verified in vivo. 
Hypoxia, a well-known feature of atherosclerotic plaques and considered to be 
pro-atherogenic [301], has been shown previously to induce the expression of ALOX15B in 
human macrophages [153]. The transcription factors mainly responsible for the hypoxic 
response are the HIFs. HIFs consist of α/β-heterodimer, the HIF-1β and three oxygen-
sensitive mammalian subunits HIF-1α, HIF-2α and HIF-3α. HIF-1β is constitutively expressed 
in the nucleus and is not affected by hypoxia. HIF-1α, the most ubiquitously expressed and 
best characterized of the family, is thought to be the master regulator of hypoxic responses 
[157]. HIF-2α has a similar regulation as HIF-1α but the expression is restricted to certain cell 
types [158]. In atherosclerotic plaques, ALOX15B expression has been found in correlation 
with HIF-1α expression as well as with the macrophage marker CD68 [192]. Additionally, in 
vitro treatment of human macrophages with the HIF-1α stabilizer DMOG led to increased 
ALOX15B expression, and the knocking down of HIF-1α decreased the production of the 
12/15-LOX metabolite 15-HETE; these findings suggest that HIF-1α modulate ALOX15B 
enzyme activity [192]. Rydberg et al. found that incubation of human primary macrophages 
under hypoxic conditions induced the expression of ALOX15B [153], which is corroborated 
by this study. Further they showed that human macrophages incubated under hypoxic 
conditions oxidized LDL in a higher amount than normoxic macrophages [153] suggesting 
that ALOX15B may contribute to the oxidation of LDL in hypoxic atherosclerotic regions. 
However, a direct contribution of ALOX15B to LDL oxidation in vitro has not yet been shown. 
Hence, there are data which support the suggestion that ALOX15B might be involved in the 
pro-atherogenic effect of hypoxia via HIF-1α and through enhanced oxidation of LDL, a key 
event in atherogenesis. However, more data are necessary to verify this theory.   
There is evidence that bacteria and viruses contribute to the development of 
atherosclerosis by triggering inflammation. LPS, the major component of the outer gram 
negative bacterial membrane and a classical pro-inflammatory stimulus, is the main ligand 
for TLR 4. In human atherosclerotic lipid-rich lesions, TLR 4 is preferentially expressed by 
macrophages and oxLDL has been shown to induce its expression in vitro [302]. 
Investigation of TLR in mouse models revealed that deficiency of TLR 4 in LDLR knockout 
mice led to markedly reduced atherosclerosis [303]. Additionally, administration of LPS to 
ApoE-/- mice, mimicking a systemic inflammation, increased the atherosclerotic lesion size 
[304]. Interestingly, investigation of TLR 4 in early stage of atherosclerosis revealed that 
deficiency of this receptor in ApoE-/- mice led to a decreased lipid accumulation in the intima 
suggesting that TLR 4 promotes early foam cell accumulation [126]. In my study I found that 
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the TLR 4 ligand LPS induced ALOX15B expression in vitro, however, whether ALOX15B 
and its metabolites are involved in the TLR 4 mediated early foam cell accumulation by 
participation in the oxidation of LDL or increased CD36 expression remains to be elucidated. 
LPS has been shown to be a non-hypoxic activator of HIF-1α expression in macrophages in 
vitro [305] leading to the suggestion that HIF-1α might participate in the pathway of the 
LPS-mediated ALOX15B expression. However, more research is necessary to verify this 
suggestion. 
All of the factors that had an effect on the ALOX15B expression in my study were 
shown to be involved in atherosclerosis. IL-4, hypoxia and LPS, which increase the 
ALOX15B mRNA and protein expression, are supposed to be pro-atherogenic. In contrast, 
IL-13 which enhanced the ALOX15B mRNA but not the ALOX15B protein exhibited 
anti-atherogenic activity. This would lead to the assumption that ALOX15B might play a 
pro-atherogenic role. This hypothesis is supported by the data of Magnusson et al. who 
demonstrated that silencing of the ALOX15B gene in human macrophages decreased 
cellular lipid accumulation and reduced the pro-inflammatory cytokine secretion in vitro [271]. 
Additionally, the only in vivo experiment so far with the ALOX15B mouse homologue known 
as ALOX8, suggests a pro-atherogenic role, as deletion of this enzyme in LDLR-/- mice 
decreased atherosclerotic plaque area, subendothelial lipid accumulation, plaque T cell 
content and plasma levels of the pro-inflammatory cytokine IL-2 [271]. Although the mouse 
homologue ALOX8 and human ALOX15B share the highest sequence identity among the 
mammalian LOXs, they exhibit different enzymatic positional selectivity leading to distinct 
metabolite production. Thus, the pro-atherosclerotic role of ALOX8 in mice might not be 
conferred on humans. In agreement with this, investigation of 12/15-LOX in different animal 
models and human resulted in conflictive outcomes, probably due to different expression 
pattern of 12/15-LOX iso-enzymes in mammals leading to distinct metabolite production. 
Hence, whether ALOX15B in human is pro- or anti-atherogenic remains to be elucidated. 
   
In the second part of this study I screened the ALOX15B gene for polymorphisms and 
found twenty three single nucleotide polymorphisms (SNP’s). Four of these are located in the 
region 1500 bp upstream of the start codon, one in the 5’UTR, nine in the coding region, six 
in the non-coding region and three in the 3’UTR region. However, I did not include all of them 
in my association study as one of the SNP’s located in the upstream region occurs with a too 
low frequency and the polymorphisms in the non-coding region might not influence the 
protein structure and therefore the enzyme activity. Only two non-coding SNP’s which were 
located in the sequenced fragment were included in the association study. Thus I 
investigated eighteen selected polymorphisms in the ALOX15B gene and analysed the 
association with CAD in our small case control study using an additive genetic model. I found 
that the polymorphisms at position c.1656G>A, c.1579+71C>T and c.1458-38G> C (OR: 
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0.51 (0.27-0.94), p-value: 0.03) show perfect linkage disequilibrium and are association with 
CAD. Additionally, the mutation at position c.705C>T (OR: 0.80 (0.62-1.03) p-value: 0.09) 
and c.1967A>G (OR: 0.81 (0.62-1.04), p-value: 0.10) showed a trend to be associated with 
CAD. The three polymorphisms p.Arg486His (c.1457G>A), p.Gln656Arg (c.1967A>G) and 
p.Ile676Val (c.2026A>G) led to non-synonymous amino acid exchanges. My collaborator, 
Thomas Horn, studied the enzyme activity and specificity of the three different mutations in 
comparison with the wild-type enzyme in vitro and found no difference in the catalytic activity 
and product specificity between the mutant proteins and the wild-type form. Further analysis 
showed that the denaturation curves and resulting melting temperatures of the different 
mutated variants did not differ much from the wild-type enzyme, with the exception that, 
p.Ile676Val has an ~ 2.4 °C decreased melting point. 
Risk prediction in atherosclerosis is currently limited to the evaluation of classic 
cardiovascular risk factors such as obesity, smoking, hypertension, family history and lipids. 
The knowledge of the individual genetic profile would permit a more detailed assessment of a 
patient’s risk for atherosclerosis [306]. In the last few years many novel genetic markers 
associated with complex human diseases have been discovered. Such polymorphisms, 
particularly located in genes which are involved in the pathways not yet associated with risk 
factors, will become useful as new risk factors for atherosclerosis and other diseases and will 
improve individual risk prediction.  
Located in the coding region, mutations can either lead to an altered amino acid 
sequence, and therefore to a different protein structure with modified enzyme activity, or be 
“silent” as they results in synonymous codon substitutions. An interesting example of a 
mutation in the ALOX15B gene has been found by Walther et al. They reported that the 
insertion or removal of a critical histidine at the active side of human ALOX15B protein 
(p.Val603His) leads to a pH-dependence of the reaction specificity. This ph-dependency has 
been found in some plant LOXs but not in wild-type isoforms of vertebrate LOXs [307]. In 
atherosclerotic plaques both conditions have been found, low oxygen as well as pH 
heterogeneity [308], which could therefore influence the reaction specificity of a modified 
ALOX15B enzyme. However, we did not detect this mutation in our case control study. 
The intronic and synonymous SNP’s have been largely assumed to not exhibit an 
effect on the gene function, however, there is emerging evidence showing the contrary. For 
example it has been shown that intronic variants can lead to exonization of intronic 
sequences or exon skipping [280, 309],  and that synonymous variants can affect the 
translational kinetics leading to a different protein conformation and consequently altered 
protein function [281, 282]. Despite these new findings, I decided to focus my association 
study on SNP’s located in the promoter, the 5’UTR, the coding and the 3’UTR region. 
  The promoter and the 5’UTR region have important roles in gene expression and 
regulation and a mutation in this area might have an impact on protein expression and 
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enzymatic activity. For example SNP’s altering a transcription factor binding site in the 
promoter can lead to different gene expression [268, 310]. Alternatively, variation in the 
5’UTR region could alter the sequence of an upstream open reading frame (uORF). uORFs 
can lead to truncated peptides and can reduce the protein expression by 30-80% without 
much impact on mRNA levels [311]. I analyzed the mutations found in the promoter region in 
silico for a change in transcription factor binding sites using genomatix software, and found 
that the polymorphisms at position c.-537 G>T would newly form a homeodomain-leucine 
zipper site and delete a NKX homeodomain factor site. Additionally, the replacement of an A 
with a G at position c.-1106 A>G deletes a NKX homeodomain factor site, cAMP-responsive 
element binding protein (CREB) site as well as an EVI1-myleoid transforming protein site, 
and would newly form a fork head domain factor site. However, these results were performed 
in silico and most of the indicated transcription factor binding sites might not play a role in the 
regulation of ALOX15B in humans. The most interesting and likely involved factor is the 
CREB transcription factor, which has been reported to participate in the IL-13 induced signal 
transduction pathway regulating ALOX15 [312], but whether this factor is also responsible for 
the ALOX15B expression remains to be clarified. However, the analysis of these SNP’s for 
an association with CAD did not result in an association in our case control study, suggesting 
that these transcription factor binding sites might not be involved in the regulation of 
ALOX15B in atherosclerosis. 
The 3’UTR region is an important segment of the mRNA and involved in the 
regulation of gene expression. Micro RNAs (miRNAs), short, endogenous, non-coding RNAs, 
function as endogenous translational repressors of genes which code for proteins, and have 
their target located in the 3’UTR region of the mRNA. Several publications suggest that 
miRNAs regulate biological processes such as cell growth, differentiation, proliferation and 
apoptosis and thus are involved in the development of diseases [313]. Many miRNAs have 
been shown to be implicated in the different processes of atherosclerosis (summarized in 
[314]), and several studies in human and mice revealed their relevance on the onset of this 
disease. For example, administration of miR-126 to ApoE-/- mice led to smaller 
atherosclerotic lesions with a less inflammatory phenotype [315]. In humans, investigation of 
atherosclerotic plaques revealed that the expression of miR-21, miR-34a, miR-146a/b and 
miR-210 were significantly increased [316]. In another study, Fichtlscherer et al. 
demonstrated that the circulating levels of miR-126, miR-17, miR-92a, miR-145 and miR-155 
are lower in patients with CAD than in healthy controls [317]. Hence, there is a potential 
effect of a polymorphism in the 3’UTR region, which could create either a new miRNA target 
site or delete a pre-existing one, and which could therefore modify the protein translation and 
efficiency [318]. I performed an analysis in silico of the detected 3’UTR variants and found 
that the mutation at position c.*226A>T is located in the sequence of miR-140-5p binding 
site. However, to date, miR-140-5p was neither detected in atherosclerotic plaques nor 
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associated with CAD and is thought to be expressed mainly in CD4 memory T cells [319]. 
Corroborating this, my association study did not reveal a correlation between the SNP 
located in the miR-140-5p binding site and CAD, suggesting that the c*226A>T and the miR-
140-5p might not be involved in atherogenesis. 
The polymorphisms I found to be associated with CAD, are located either in the 
non-coding region (c.1579+71C>T and c.1458-38G>C) or result in synonymous 
polymorphisms (c.1656G>A), which makes it difficult to predict a functional effect and 
therefore to state the role of ALOX15B in human atherosclerosis. However, as described 
before, there is evidence that the intronic and synonymous SNP’s might not be “silent” and 
could influence the protein or enzyme activity. But, even though my data indicate an 
association with CAD, our case control study with 496 participants is too small to detect an 
association with enough power and statistical significance. A larger study would be 
necessary to confirm the association of these polymorphisms with CAD before a potential 
effect of these polymorphisms on the ALOX15B protein function should be investigated. With 
these functional results, it would be possible to define whether ALOX15B is pro- or 
anti-atherosclerotic in humans.   
  I also observed a trend for an association of the synonymous SNP c.705C>T and of 
the non-synonymous SNP c.1967A>G (p.Gln656Arg) with CAD. However, in vitro 
measurement of the enzyme activity and specificity revealed no difference in the catalytic 
activity and product specificity between the mutant (p.Gln656Arg) and the wild-type form. In 
addition, investigation of the enzyme properties showed that the Michaelis-Menten 
parameter, the turnover numbers kcat and the Michaelis constant Km values of the SNP, are 
similar to the wild-type enzyme. Furthermore the analysis of denaturation curves and melting 
temperatures did not differ between the mutant and the wild-type ALOX15B enzymes. Thus, 
the exchange of the amino acid at position 656 did not alter the enzymatic properties of 
ALOX15B. Additionally, none of the investigated non-synonymous variants (p.Arg486His, 
p.Gln656Arg und p.Ile676Val) differ from the wild-type in their enzymatic and thermodynamic 
behavior. Only p.Ile676Val has a decreased melting point (~ 2.4 °C) indicating that this 
mutation might destabilize the tertiary structure of the protein. However, because of the small 
temperature alteration we do not expect a functional impact on the enzyme activity in vivo. 
Therefore, the lack of a functional impact of the investigated non-synonymous 
polymorphisms in the coding region of ALOX15B suggests that this enzyme is highly 
conserved in Europeans and that it might be important. 
 
In conclusion, I found in vitro that ALOX15B is the main 12/15-LOX expressed in 
human macrophages and is regulated by several cytokines and hypoxia which are involved 
in atherosclerosis, suggesting a possibly pro-atherosclerotic role for this enzyme. 
Furthermore, the study of several polymorphisms of the ALOX15B gene in humans revealed 
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that three rare and completely linked variants are associated with CAD. However, larger 
studies with the necessary power are required to specify the role of ALOX15B in 
atherosclerosis in humans. Although my findings indicate a possible involvement of 
ALOX15B in atherosclerosis, the results of my thesis did not solve the question whether 
ALOX15B has pro- or anti-atherosclerotic activity and more research would be necessary to 
clarify the role of ALOX15B in atherosclerosis. 
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